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Executive Summary 
The present study was commissioned by, and conducted within, Merchants Quay Ireland 
(MQI). Within the spectrum of facilities offered in Dublin, MQI Open Access provides 
frontline homeless and drug services. A cornerstone of the open access drug service is the 
Health Promotion Unit - Needle Exchange.  The main objectives of the Health Promotion 
Unit are concerned with minimising the harms associated with drug use and educating drug 
users on the potential risks. The primary aim of the present study was to gain an up-to-date 
profile of the clients accessing the Health Promotion Unit with a view to providing an 
informed platform for service provision.  
Overview of Key Research Findings 
 A total of 338 participants took part in the study. The sample consisted of 290 males 
(86%) and 48 females (14%). The male to female gender ratio of approximately 6:1 
observed in the present study is notably higher than those found in most European and 
Irish studies. 
 
 The mean age for males was approximately 34 years and the mean age for females 
was approximately 32 years. The age distribution found in the present study echoes a 
general trend identified across drug studies which have observed that the population 
of Irish opiate users is ageing.  
 
 Although the majority of participants were Irish nationals (88%), the sample was 
made up of nineteen different nationalities, which highlights the ethnic diversity in 
those frequenting the Health Promotion Unit - Needle Exchange at MQI.  
 
 The results highlighted that the majority of MQI service users are Dublin based. 
Indeed, only 9% resided outside Dublin, and only 4% resided outside Leinster. 
 
 Approximately 31% of participants in the present study were residing in categories 
which were classified as homeless.  
 
 Heroin was the most prevalently used substance in the past month (86%). Use of 
prescribed methadone (49%), benzodiazepines (34%; illicit 18%, prescribed 16%), 
cannabis (24%) and alcohol (22%) was also prevalent. Steroids (7%), cocaine (6%), 
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mephedrone (6%), crack (6%), other (4%), illicit methadone (2%) and amphetamines 
(1%) were all used by less than 1 in 10 participants within the past month. 
 
 A large majority of participants were poly-substance users (75%). Approximately 
30% of the sample reported use of two substances over the past month, 25% reported 
use of three substances, 12% reported using four substances and 6% reported using 
five substances. Less than 2% of participants reported use of more than five 
substances within the past month.   
 
 Almost all of the participants attending the Health Promotion Unit - Needle Exchange 
were injecting drug users (97%). 51% of participants reported injecting 6 or more 
times in the past week. 
 
 Approximately three-quarters of the sample reported use of only one main injection 
site. Almost a third of participants reported injecting in to either the groin or the neck. 
 
 Overall, approximately 27% of respondents reported incidences of sharing injecting 
equipment and paraphernalia in the past month. The overall rates of sharing of items 
were water (13%), tourniquets (12%), cookers (10%), syringes (10%), filters (9%), 
frontloading (8%), needles (7%) and backloading (5%). 
 
 During the past week; around 41% reported generally injecting with other people and 
59% reported injecting on their own; almost 88% reported generally injecting 
themselves and just over 12% reported being generally injected by another person/s; 
almost 86% of respondents had generally been injecting in a private domain and just 
over 14% had generally been injecting in a public area. 
 
 Almost four-fifths of participants reported that they had been tested for HIV. The 
prevalence of HIV reported by those who had been tested was 8.33%. Approximately 
55% of the participants who reported being negative for HIV had not been tested 
within the past year. Uptake of treatment for those who reported being positive for 
HIV also appears to be a problematic issue.  
 
 Just over four-fifths of the sample reported being tested for Hepatitis C. The 
prevalence of Hepatitis C reported by those who had been tested was approximately 
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45%. Approximately 37% of the participants who reported being negative for 
Hepatitis C had not been tested within the past year. Another significant concern was 
the low rate of participants accessing treatment for Hepatitis C.  
 
 Approximately 78% of participants reported that they had ever been tested for 
Hepatitis B. The prevalence of Hepatitis B reported by those who had been tested was 
approximately 5%. Approximately 48% of participants who had previously tested 
negative for Hepatitis B had not been tested within the past year.  
 
 The prevalence of Hepatitis C/Hepatitis B co-infection was approximately 3% for 
those who had been tested for both viruses.  The prevalence of HIV and Hepatitis C 
co-infection was approximately 6% of those who had been tested for both infections. 
One participant also reported being positive for HIV, Hepatitis B, and Hepatitis C. In 
combination this indicated that almost 73% of those who were HIV positive were also 
Hepatitis C positive.  
Recommendations 
Research represents a primary pillar of the National Drugs Strategy (Interim) 2009-2016, in 
which, the strategic aim of ensuring the availability of accurate, timely, relevant and 
comparable data on the extent and nature of problem substance use in Ireland, is emphasised. 
Contemporary research within the context of low threshold services and needle exchange 
programmes in Ireland is particularly sparse. Consequently, there is paucity of germane data 
available for evidence informed decision-making and policy formulation in this domain. The 
present study offers a contribution towards fulfilling national policy research objectives, and 
provides a foundation for the construction of an up to date evidence base in relation to Irish 
harm reduction services. Based on the research process and findings presented herein, a 
number of recommendations are proposed:   
Policy Based Recommendations 
 Sharing of injecting equipment and paraphernalia persists. The National Drugs 
Strategy (NDS) document Building on Experience (2001-2008) advocates that in 
order to reduce “the reported level of injecting drug misuse and the rates of sharing 
injecting equipment” (pp. 110) there should be “continued efforts to enhance harm 
reduction measures such as needle exchange facilities” (pp. 110) and “access for all 
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injecting drug misusers to sterile injecting equipment” (pp. 124). In this regard, there 
is a need to ensure that needle exchange programmes are providing injecting 
equipment consistent with guidelines recommended in the international research (e.g. 
Strike et al., 2006) so as to optimise harm reduction.  Where deficits are identified in 
the provision of injecting equipment, reasons for these gaps should be examined and 
communicated to Health Service Executive suppliers, in the effort to eliminate 
equipment related barriers in supporting safer injecting practices among injecting drug 
users. 
 
 A major finding of the present study is the prevalence of blood-borne viruses (BBVs), 
coupled with insufficient levels of testing and low rates in uptake of treatment for 
Hepatitis C and HIV. Furthermore, the results indicate that frequency of testing is a 
concern. The evidence in previous studies suggests that convenience is an important 
factor for injecting drug users in management of BBVs and low-threshold services are 
ideally placed to attract clients which have not been previously screened. The 
recommendation that screening is offered and promoted within harm reduction 
services, as advised by the National Hepatitis C strategy 2011-2014, the European 
Centre for Monitoring Disease and Drug Addiction (2010) and the World Health 
Organisation (2010), is therefore supported.  
 
 The proportion of assisted injecting and injecting in public places reported in the 
present study represents a significant amount of injecting drug users who are at 
elevated risk of severe health consequences. An emerging strategy designed to combat 
such risks is the development of medically supervised injecting centres (MSIC). Such 
amenities are currently not available in Ireland and such a strategy is not endorsed 
through national policy. Reference to drug consumption rooms was made in the 
National Drugs Strategy (NDS) document Building on Experience 2001-2008 which 
stated ‘the Review Group does not consider that the introduction of such forms of 
treatment is warranted at this time. However, the situation should be kept under 
review and the results of research, both national and international, should be 
monitored’ (Section 4.13.3.). The National Drugs Strategy (Interim) 2009-2016 
makes little elaboration on the issue. It is therefore advised that in line with the 
recommendation from the Strategic Response Group’s ‘A Better City for All’ report 
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(Connolly, 2012), further consideration of safer injecting facilities in an Irish context 
is warranted in future national policy deliberations.  
Research Based Recommendations 
 The present study provides additional evidence that the population of Irish opiate 
users is ageing. As the needs of older drug users tend to be more complex, future 
research should address if services are structured to cater for impacts which may 
accompany this shift in age profile.   
 
 The gender ratio found in the present study supports previous findings which indicate 
that females may be under-represented in drug services. Future research should aim to 
explore the potential barriers for female drug users and investigate appropriate 
gender-specific approaches.  
 
 As indicated by the present study, the level of substance use among the homeless 
population continues to present concern. As stated in the National Drugs Strategy 
(Interim) 2009-2016, gaps in the provision of treatment services for homeless drug 
users persist. Further research in the vein of Corr and Lawless (2005) is necessary to 
update research regarding meeting the needs of homeless drug users.   
 
 The present study indicates a high prevalence of poly-drug use and highlights the 
current patterns of use. Future research should examine needs, impact, harm reduction 
interventions, and treatment and rehabilitation options in relation to poly-drug use.    
 
 There has been little published data in Ireland regarding steroid use, or steroid users’ 
engagement with services. The findings of the present study are consistent with 
international and Irish research which suggests that steroid users are becoming more 
prevalent in harm reduction services. As a marginalised group with divergent 
characteristics, there is the need to develop an evidence base which explores the 
profile of harm within this group, and to identify tailored approaches within the 
context of low threshold services.   
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 Findings for sharing of injecting equipment and paraphernalia in the present study 
were incongruous with results from previous research. Future research should further 
investigate rates of sharing and consider the appropriateness of conducting related 
research in the context of needle exchange services.  
 
 Findings concerning BBVs in the present study were based on self-report. In order to 
ascertain a definitive prevalence, future research which incorporates serological 
testing is advisable.  
 
 A significant concern presented by the current study is management of Hepatitis C in 
injecting drug users. As noted in the National Hepatitis C strategy 2011-2014, 
evaluation of different models of care is needed to address the range of barriers faced 
by injecting drug users so as the enhance treatment access, delivery, and adherence.  
Practice Based Recommendations 
 There are varied issues and barriers around service access and service use amongst 
female and migrant drug users. It is recommended that services make continued 
efforts to adopt a pro-active stance in regard to these groups.   Service providers 
should monitor the level of service use by under-represented groups (e.g. numbers, 
profile and needs of under-represented groups) to ensure that services are attracting 
members of these groups and meeting their needs. A gendered approach which 
recognises the needs unique to females is advocated. In the effort to address barriers 
faced by migrant drug users to accessing services, implementation of the 
recommendations from Corr (2004) are advised: translated materials could help 
breach the language barrier and increase knowledge and perceived accessibility of 
services; outreach could help interaction with underrepresented migrant groups; 
recruitment of staff from such backgrounds could help to attract and engage users 
from these communities; and more flexible and appropriate services could respond to 
unique needs more effectively. 
 
 It is vital that services are familiar with the profile of poly-drug use among their client 
base and are able to identify individual harm reduction needs. The provision of 
continuous up-skilling for staff is necessary to offer appropriate harm reduction 
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advice and to address the risk behaviours associated with different patterns of drug 
use. The same applies in emerging areas such as steroid use.  
 
 Given the prevalence of BBVs found in the present study, as well as the concerns 
presented in relation to access to testing and uptake in treatment, it is recommended 
that in the case on-site BBV management options are not available; services should 
further develop collaborative relationships with appropriate external agencies. It is 
further advised that ongoing up-skilling with regard to BBV education, testing 
regimes, and treatment options, is provided for staff.  
  
 A high proportion of high risk behaviours such as injecting in to the groin/neck and 
not rotating injecting sites were found in the present study. Thus, the findings 
highlight the importance of the role of safer injecting workshops and suggest that 
there is a need to ensure that every effort is being made to direct clients to such a 
service. Services should encourage client participation in safer injecting workshops 
irrespective of whether clients are newly injecting or have longer injecting careers. 
 
 Drug use does not exist in isolation. The complex of personal and structural problems 
faced by drug users, particularly those who are homeless, requires a multi-disciplinary 
approach to address their needs.  Services should continue to strive to provide a case 
management approach that is client-centred.  Such an approach requires greater 
collaboration and integration across the range of voluntary and government 
organisations involved in the provision of homeless, drug, and health services. Re-
skilling of staff in providing a multi-disciplinary spectrum of care also requires 
increased interagency transfer of training knowledge. 
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1. Introduction 
1.1. Background to the study 
The present study was commissioned by, and conducted within, Merchants Quay Ireland. 
Originally established in 1989, the Merchants Quay Project initiated a range of services for 
people affected by drug use and HIV. In 1996, a homeless service was introduced designed to 
cater for the daytime needs of homeless people. In 2001, the homeless and drugs services 
operating at Merchants Quay were brought together under one management structure and 
became Merchants Quay Ireland (MQI). In response to the growing incidence and 
acknowledgement of the geographical diffusion of poverty, social exclusion, homelessness 
and problematic drug use over the last decade, the organisation has expanded significantly, 
and is currently in operation in eleven counties across Ireland.  
Within the spectrum of facilities offered in Dublin, MQI Open Access provides frontline 
homeless and drug services. A cornerstone of the open access drug service is the Health 
Promotion Unit - Needle Exchange.  The main objectives of the Health Promotion Unit are 
concerned with minimising the harms associated with drug use and educating drug users on 
the potential risks. Accordingly, the primary focus is on HIV and Hepatitis prevention, 
promoting safer injecting behaviours and techniques, providing information on associated 
risks and offering users a pathway in to treatment.  
A further aim of the Health Promotion Unit is to evaluate changes and trends in drug use and 
associated behaviours. The availability of research within the landscape of drug services has 
witnessed a dramatic downturn in recent years due to the economic impact of the recession. 
As a result, current trends can only be estimated through previous, anecdotal or non-specific 
evidence. MQI open access services in Dublin have recently moved to the new Riverbank 
Centre located on Merchants Quay. Consequently, 2013 presents fresh challenges for the 
organisation and represents a prime time for exploration of the Health Promotion Unit. As 
outlined in the next section, the principal purpose of the present study was to gain an up-to-
date profile of the clients accessing the Health Promotion Unit, allowing the service to 
investigate and benchmark current trends, and to develop an informed platform for decision-
making. It also offers a step towards standardising data collection within the service with a 
view to providing a practical framework and methodology for future research.  
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1.2. Research Aims 
 To attain an up-to-date profile of clients presenting to the Health Promotion Unit at 
Merchants Quay Ireland 
 
 To examine the socio-demographic characteristics of clients  
 
 To investigate current levels and trends of drug use, and identify patterns of poly-drug 
use 
 
 To explore frequency and manner of injecting risk behaviours 
 
 To gain a portrait of the prevalence of blood-borne viruses, and associated treatment 
status  
 
 To provide an evidence base, which could be incorporated in to future policy, 
research and service provision 
 
 To identify strengths and deficiencies, and facilitate possible adaptation of services to 
better cater for the needs of the client base  
 
 To contribute to the community of discourse surrounding harm reduction research, 
policy and practice 
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2. Literature Review 
2.1. Harm Reduction 
2.1.1. Harm reduction. As defined by the World Health Organisation (WHO), harm 
reduction refers to a concept aiming to prevent or reduce negative health consequences 
associated with certain behaviours (WHO, 2003). Interventions designed to reduce harm have 
long been applied in the public arena. In everyday contexts, features such as speed limits and 
car seatbelts serve as strategies to minimise harm from behaviours which may generate 
negative health outcomes (HRSS, 2010). Harm reduction, as it relates to drug use, is a 
relatively modern approach and “encompasses interventions, programmes and policies that 
seek to reduce the health, social and economic harms of drug use to individuals, communities 
and societies” (Rhodes & Hedrich, 2010; p. 19).  
Traditionally, international drug policy had mandated a focus on drug control measures 
which advocated prevention and abstinence. The relationship between drug policy and public 
health had long been recognised, with the collective aim of improving the health of 
populations, preventing ill-health and disease, and promoting well-being. However, in 
response to heightening awareness of the public health concerns emerging in the early 1970s, 
a paradigm shift in drug policy was called for, encouraging a transition towards a harm 
reduction directive, which prioritised public health over drug control (Ball, 2007). With the 
emergence of global blood-borne virus epidemics in the proceeding decades, an international 
harm reduction movement has gradually evolved. Harm reduction has become a mainstream 
pillar of international drug policy, employed in particular as an agent intended to minimise 
the risk factors associated with the contraction and transmission of blood-borne viruses 
(BBVs) such as human immunodeficiency virus (HIV), Hepatitis B (HBV) and Hepatitis C 
(HCV).  
As a central tenet, the philosophy of the harm reduction model pragmatically accepts that 
drug use is a prevailing reality and acknowledges the self-determination of those who choose 
to use drugs. Within this ethos, public health, which encompasses both the personal and 
social components, is the prime concern. Hence, rather than directly concentrating on 
prevention or abstinence, primary focus is placed on reducing the incidence and impact of 
drug related harm, and facilitating accessible pathways in to drug services. Within this 
framework, the notions of abstinence and harm reduction are not considered mutually 
exclusive or dichotomous extremes. While reducing harm may be delineated as the focal 
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objective, contemporary visions of harm reduction conceptualise it as a “combination 
intervention” that is comprised of a variety of interventions adapted to the diversity of 
settings, systems and populations in which it is operationalised (Rhodes & Hedrich, 2010). 
As stated on their website, the World Health Organisation (WHO) “strongly supports harm 
reduction as an evidence-based approach to HIV prevention, treatment and care for people 
who inject drugs”. The WHO actively encourages the implementation of a comprehensive 
strategy of harm reduction which includes “needle and syringe programmes, drug dependence 
treatment - in particular opioid substitution therapy, HIV testing and counselling, HIV 
treatment and care information, education and risk reduction counselling, condom 
distribution and STI management, management of tuberculosis and viral hepatitis”. A number 
of other international bodies including the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the United 
Nations Office on Drugs and Crime (UNODC) are also proponents of the harm reduction 
approach. Accordingly, harm reduction is currently endorsed in policy or practice in 
approximately ninety-seven countries and territories (IHRA, 2012).    
2.1.2. Harm reduction in Ireland. Butler (1991) describes that similar to the 
examples seen in other countries, the development of harm reduction practices emerged in 
Ireland in the late 1980s in response to the threat of HIV and the identification of injecting 
drug users as a high risk group for contracting and transmitting the virus. As a consequence, 
methadone maintenance and needle exchange programmes were introduced, designed in 
particular to reduce the incidence of needle sharing, which had been recognised as a major 
risk factor in the transmission of HIV. As part of the needle exchange programme, outreach 
services were also developed which sought to establish links with drug users.  
On a policy level, the shift away from the dominant prevention and abstinence based 
strategies was first endorsed by the Government Strategy to Prevent Drug Misuse (1991). In 
light of a developing understanding of the complex dynamics involved in drug use, Irish drug 
policies and practices have increasingly adopted a harm reduction strategy over the last two 
decades. The National Drugs Strategy (NDS) document Building on Experience 2001-2008 
was created with the overarching strategic objective “to significantly reduce the harm caused 
to individuals and society by the misuse of drugs” to be achieved through “a concerted focus 
on supply reduction, prevention, treatment and research” (NDS; pp. 10). The National Drugs 
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Strategy (Interim) 2009-2016 further advocates the continuing development of harm 
reduction.  
2.1.3. Issues surrounding harm reduction. Despite a growing evidence base, which 
strongly supports the efficacy of harm reduction, there is continuing debate surrounding the 
approach. Critics have argued that harm reduction provides a safety net that enables and 
perpetuates drug use, and is associated with the movement towards the liberalisation of drug 
legislation (Hunt et al., 2003). Some authors have also suggested that the focus on drug 
dependence has been somewhat lost within the harm reduction shuffle, with services 
overlooking the harm caused to the individual by the addiction itself (Negete, 2001).   
A further issue within the harm reduction paradigm is that there is no agreed upon formal 
definition of harm reduction and it is commonly used indiscriminately as an umbrella term to 
simultaneously describe a principle, concept, ideology, policy, strategy, set of interventions, 
target and movement (Ball, 2007). For practical purposes, there is general consensus on how 
harm reduction should ideally be operationalised, however the ambiguity surrounding the 
interpretation of the term has led to the differential application of harm reduction across the 
global landscape. Moreover, some countries employ harm reduction as a strategy which is 
explicitly endorsed through national policy, while other countries have developed programs 
such as Needle and Syringe Programmes (NSP) and Opioid Substitution Therapy (OST) 
without the overt support of policy (IHRA, 2012). Concerns over the challenges of 
developing harm reduction approaches in low- and middle-income countries have also been 
raised, pointing to the need for research designed to examine whether harm reduction 
programmes would be viable in contexts which face economic and political uncertainty and 
extreme public health issues (IHRA, 2012). 
2.2. Needle Exchange Programmes 
2.2.1. Needle exchange programmes. Originally conceived as an intervention 
response to the epidemic of BBVs emerging in Edinburgh (Burns et al., 1996) and 
Amsterdam (Buning et al., 1986) in the early 1980s, needle exchange programmes have since 
been gradually implemented on an international scale. Within the harm reduction ethos, 
needle exchange programmes play a central role in reducing drug-related harm, particularly 
in the attempt to minimize the risk factors associated with the contraction and transmission of 
BBVs such as HIV, Hepatitis B and Hepatitis C, and to reduce the prospect of bacterial 
infections. These services supply clean needles and syringes to injecting drug users (IDUs) 
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and allow for the safe disposal of used equipment. Injecting drug use involves multiple 
processes and requires a range of ‘Injecting paraphernalia’, which is the collective term used 
to describe equipment used by IDUs in the preparation and administration of drugs for 
injection (Scott, 2008). Therefore, NEPs may also distribute a range of paraphernalia such as 
cookers, filters, alcohol swabs, sterile water, and critic acid. Such equipment offers clients the 
means for safer injection. This is supplemented with health education to inform clients on the 
harms associated with injecting drug use and the sharing of drug injecting equipment. NEPs 
often act as the first point of contact for drug users, facilitating initial connection with drug 
services in a non-judgmental interaction, providing access to health services, and opening 
avenues for further treatment options (Kuo et al., 2003). 
Needle exchange programmes have been extensively researched and evaluated. As a 
consequence, a substantial body of evidence has been established which indicates that needle 
exchange provision is an effective element of public health strategies and a fundamental 
component in the architecture of harm reduction systems. A review of effectiveness studies 
spanning 1989-2002 conducted by the World Health Organisation (Wodak & Cooney, 2004) 
offers considerable support for needle exchange programmes, most notably, that provision of 
sterile injecting equipment lessens the occurrence of HIV infection, and does so in a cost 
effective manner. Furthermore, it was found that programmes provide additional benefits 
such as increased transition in to drug treatment and primary healthcare, and does not seem to 
stimulate amplified initiation, duration or frequency of drug use. There is however the caveat 
that reduction of risk-behaviour is not achievable through provision of sterile injecting 
equipment alone, and must be supplemented by appropriate support and education structures. 
Needle exchange programmes are in operation in at least seventy-seven countries worldwide 
(Cook, Lines, Stimson, & Bridge, 2009) and have received significant endorsement from the 
World Health Organisation as a means of HIV prevention (WHO, 2003; Wodak & Cooney, 
2004). 
2.2.2. Needle exchange programmes in Ireland. As part of the growing movement 
towards a harm reduction approach emerging in the late 1980s, needle and syringe exchange 
services were first introduced in Ireland in 1989, with the establishment of five exchange 
programmes (Butler & Mayock, 2005). Needle exchanges are explicitly endorsed by Irish 
policy. The National Drugs Strategy (NDS) document Building on Experience 2001-2008 
advocated that in order to reduce “the reported level of injecting drug misuse and the rates of 
sharing injecting equipment” (pp. 110) there should be “continued efforts to enhance harm 
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reduction measures such as needle exchange facilities” (pp. 110) and “access for all injecting 
drug misusers to sterile injecting equipment” (pp. 124). The National Drugs Strategy 
(Interim) 2009-2016 further encourages the expansion of Opioid Substitution Treatment and 
(OST) Needle Exchange Programmes (NEPs) in the co-ordinated effort to address drug use 
issues. As of 2008, there were thirty-four needle exchanges programmes in Ireland which 
operated a number of models of service including fixed-site exchanges, home visit exchanges 
and exchanges in public locations (Robinson, Gibney, Keane, & Long, 2008).  
2.2.3. Issues surrounding needle exchange programmes. As stated by Strike and 
colleagues (2006) the effectiveness of needle exchange programmes is mediated by their 
accessibility, ability to attract and retain clients, and to encourage/facilitate behaviour change. 
To these means, a variety of models of services have been developed internationally 
including centre-based/fixed-site, outreach/mobile, home-visits, pharmacies, peer-based, and 
vending machines. Differing elements such as local conditions, funding and staffing 
availability (NACD, 2008), combined with varying IDU characteristics such as age, gender, 
culture, personal preferences and financial resources, means that services need to be tailored 
accordingly (Strike et al., 2006). The appropriateness of each mode is dependent on how the 
service delivery meets the client needs within the available resources, with the primary 
objective of providing ease of access for IDUs to engage with these services. 
Given the variation in services and clients, needle exchange programmes may need to retain a 
degree of flexibility and adaptability in regard to structure and operations. That being said, 
throughout international harm reduction studies, there is an evident lack of consistency across 
policies and services in relation to the provision of sterile injecting equipment. Within 
England, figures indicate that only 25-50% of needle exchange services supply cooking 
equipment and filters (Abdulrahim, Gordon, & Best, 2007) with service providers stating that 
lack of funding often restricts best practice (Griesbach, Abdulrahim, Gordon, & Dowell, 
2006). Best practice guidelines recommend that in order to minimise the risk of viral and 
bacterial infection, and other drug-related harm, needle exchange programmes must supply a 
comprehensive array of injecting equipment and paraphernalia, which should consist of 
sterile needle and syringes, single-use cookers, sterile water, acidifiers, filters,  sterile alcohol 
swabs, tourniquets and foil (Strike et al., 2006). Although best practice may not always be 
practical or realistic due to a lack of resources or expertise, services should aim to move 
towards best practice.  
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2.3. Problem Drug Use 
2.3.1. Problem drug use. As defined by the European Monitoring Centre for Drugs 
and Drug Addictions (EMCDDA), problem drug use refers to injecting drug use or long 
duration/regular use of opioids, cocaine and/or amphetamine. Injecting drug use has been 
documented in at least 158 countries and territories worldwide (Cook & Kanaef, 2008). 
Estimates suggest that there are approximately 16 million (range 11-21million) injecting drug 
users globally (Mathers et al., 2008). The past half century has witnessed a wide geographical 
diffusion of injecting drug use, with a phenomenon, which was once predominantly confined 
to North America and Europe, extending across the world.  Epidemiological studies show 
that 78% of IDUs currently reside in developing and transitional countries (Aceijas, Stimson, 
Hickman, & Rhodes, 2004).  
Heroin, cocaine and amphetamine-type-stimulants are the most prevalently injected drugs 
(Cook & Kanaef, 2008). Within Europe, problem drug use consists primarily of opioid use, 
with the greatest social, personal and public health consequences stemming from injecting 
heroin use (EMCDDA, 2011). The most recent estimations indicate that there are 
approximately 1.3 million problem opioid users within the European Union/Norway 
(EMCDDA, 2011). Within this region, the average prevalence of problem opioid use is 
estimated to be between 3.6 and 4.4 cases per 1 000 population aged 15–64 (ECMDDA, 
2011). Ireland ranks among the EU countries with the highest levels of problem opioid use, 
with a documented prevalence of 6.2-8.1 cases per 1000 population aged 15–64. The most 
current data available regarding prevalence of opiate drug use in Ireland comes from a 
national study conducted in 2006 (Kelly, Teljeur, & Carvalho, 2009) which updated a similar 
study which took place in 2001 (Kelly, Carvalho, & Teljeur 2003). The findings from this 
study estimated that the prevalence of opiate users in Ireland was between 18,136 and 23,576, 
which represented an overall increase of 42% in opiate users from 2001-2006. The magnitude 
of this rise should however be interpreted with caution due to some of the methodological 
concerns evident in the source study.  
2.3.2. The socio-demographics of problem drug use. The global population of 
problem drug users is comprised of an ever expanding range of individuals with diverse 
features and divergent needs. However, a number of key socio-demographic characteristics 
are highly relevant within the spectrum of drug use. Most significantly, prevalence of 
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problem drug use and risk behaviours has been found to be associated with a range of 
variables including gender, area of residence, housing status, and social marginalisation.  
2.3.2.1. Gender. Research has consistently demonstrated differences in the gender 
distribution of injecting drug users, namely that IDUs are more likely to be male. 
Approximately 70-75% of IDUs in Europe and North America, and up to 90% in Asia, are 
men (Aceijas et al., 2004).The most recent estimated prevalence of opiate users in Ireland 
approximated that 71% are male (Kelly et al., 2009) and almost 75% of opiate users entering 
treatment in Ireland are male (Cox & Comiskey, 2007). Previous research with IDUs in the 
context of Merchants Quay have observed 75.7% male (Geoghegan, O'Shea, & Cox, 1999) 
and 77% male (Cox & Lawless, 2000) among new clients.  
A common theme emerging from research in the mid-late nineties was that female IDUs were 
a ‘hard to reach’ group and were under-represented at drug treatment services (Lawless, 
2003). Female IDUs have been found to be more likely to engage in injecting risk behaviour, 
sharing needles and injecting equipment more frequently than their male counterparts 
(Montgomery et al., 2002). Female IDUs are also more likely to have sexual partners with 
whom they inject drugs (Evans et al., 2003) and are more likely to be living with a drug 
misusing partner (Fagan, Naughton, & Smyth, 2008).Therefore, female IDUs represent a 
highly vulnerable group in relation to BBVs.  
This gender distribution is particularly relevant on a harm reduction service level. Literature 
has suggested that the difficulties encountered by male and female drug users differ 
significantly (Copeland, 1997), with women facing heightened barriers to accessing services 
(Hunter & Judd, 1998), higher levels of medical and psychological problems (Geoghegan et 
al., 1999) and a lack of services catering for problems specific to females (DAWN, 1994). 
Female drug users with children reported that they mistrusted drug services and feared that if 
they presented as a drug user that their children would be taken away (Taylor, 1993). It was 
also found that a majority of women were reluctant to utilise needle exchange services as 
they were more affected by the stigma associated with drug use (Barnard, 1993).  
2.3.2.2. Area of residence. Research shows that injecting drug use does not tend to be 
randomly distributed across the population as prevalence figures for problem drug use are 
higher in urban areas (ECMDDA, 2011). In the case of Ireland, early studies showed that the 
proliferation of opiate use originated in Dublin, with a large concentration of users residing in 
inner city areas where poverty and unemployment were endemic (Dean, Bradshaw, & 
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Lavelle, 1983; O’Kelly, Bury, Cullen, & Dean, 1988). As a result, intravenous drug use was 
held to primarily be a Dublin based phenomenon (O’Higgins, 1998). The past decade has 
witnessed a geographical spread in opiate use and a corresponding dispersal of drug services. 
Based on data from 2006, Kelly and colleagues (2009) estimated that almost 28% of opiate 
users in Ireland resided outside Dublin.  
Although figures for opiate use by county are not available, the number of clients accessing 
methadone treatment provides a useful indicator of geographical prevalence (HSE, 2011). 
Treatment services in the HSE Dublin Mid Leinster region and Dublin North East region 
remain the most accessed programs, though both regions only witnessed a 5% increase in the 
number of clients in the period from 2007-2011. While the overall treatment numbers remain 
much lower in the HSE South region and HSE West region, these areas observed increases of 
286%, and 48%, respectively. This suggests that opiate use is remaining relatively stable in 
Dublin and the surrounding areas but increasing dramatically in the South and West of 
Ireland. 
2.3.2.3. Housing status, migrants and social marginalisation. A consistent finding in 
the research literature is that the prevalence of drug use is significantly higher among the 
homeless population than the general population (Cox and Lawless, 2000). An illustration of 
the magnitude of homelessness as a risk factor for drug use is evident in the results from an 
Australian based study, which revealed that homeless people were 7.5 times more likely to be 
dependent on heroin when compared to the general population (Horn, 1999). The scale of 
homelessness in Ireland is highlighted by the most recent figures released by the Central 
Statistics Office which found that around 3,800 people were counted in homeless 
accommodation and rough sleeping on census 2011 night (CSO, 2012). The geographical 
distribution within this count showed that over 60% were based in Dublin.  
Homelessness has also been linked to increased levels of injecting risk behaviour (Cox & 
Lawless, 2000; Donoghoe, Dolan, & Stimson, 1992). Although previous research has found 
that drug use is predominantly initiated prior to becoming homeless, changes in patterns of 
drug use as a result of becoming homeless have been reported, with elevated frequency of 
drug use and initiation in to using different types of drugs (Wright, Oldham & Jones, 2005; 
Fountain & Howes, 2002; Cox & Lawless, 2000). Sharing of injecting equipment is also 
more common among homeless drug users (Aidala et al., 2005; Cox & Lawless, 2000). A 
higher prevalence of BBVs has been found among homeless drug users in comparison to 
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those in stable accommodation (Corneil et al., 2006; Rhodes et al., 2006a). Unstable housing 
has also been implicated as an influence in nonadherence to HIV treatment (Pach, Cerbone, 
& Gerstein, 2003).  
Such elevated risk and vulnerability may be connected not only to individual factors but also 
to structural and contextual factors. It is widely acknowledged within the research literature 
that the environment in which drug use takes place impacts the level of associated harm (e.g. 
Rhodes, 2002). Homeless injecting drug users may lack private facilities in which to inject 
and therefore, are more likely to inject in public places (Klee & Morris, 1995).  
The robust link between problematic drug use and social exclusion has long been established 
with low educational levels, unemployment, low income, insecurity of accommodation and 
homelessness all demonstrating an association with drug use (ECMDDA, 2003). Migrants 
have been found to be an at-risk population for social exclusion (ECMDDA, 2003) and 
unsurprisingly given the covariance; research has also identified a connection between drug 
use, social exclusion and ethnicity (Fountain, 2004; Corr, 2004). In addition to the usual 
elements of social exclusion, migrants also experience stresses such as displacement, seeking 
asylum and lack of social and community support which constitute further risk factors for 
engagement in drug use (Corr, 2004). Migrants who are drug users may face a double stigma 
which increases the level of marginalisation they encounter (Domenig,  Fountain,  Schatz, & 
Broring, 2007).  
2.4. Blood-borne Viruses 
Injecting drug use has been consistently found to be a serious risk factor for blood-borne 
virus infection, particularly in the case of human immunodeficiency virus, hepatitis C virus 
and hepatitis B virus. Research over the past two decades has primarily implicated injecting 
risk behaviour, such as sharing of injecting equipment and paraphernalia, as the principal 
cause of transmission. HIV and HBV can also be sexually transmitted creating a further risk 
factor for drug users who engage in sexual risk behaviour such as unprotected sex and 
prostitution. In addition, there is the risk of virus transmission from injecting drug users to the 
general population from the improper disposal of injecting equipment and through sexual 
contact.  BBVs present severe personal and public health consequences, increasing the risk of 
morbidity and mortality, as well as impacting public health costs.   
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2.4.1 HIV. When infected, the HIV virus is present in all bodily fluids. Thus, there 
are a variety of possible modes of transmission which include sexual intercourse, mother to 
foetus, contaminated blood products, and injection with unsterile needles (Long, 2006). As 
previously stated, the move towards the harm reduction model evolved primarily from the 
growing epidemic of HIV infection witnessed among injecting drug users. Research has 
estimated that approximately 10% of global HIV cases have occurred from injecting drug use 
(Aceijas et al., 2004).  Out of the 16 million IDUs worldwide, reports indicate that in the 
region of 3 million of these are estimated to be infected with HIV (Mathers et al., 2008).  
There are however large geographical variances in HIV prevalence among IDUs. Reports of 
HIV among IDUs have been documented in 120 countries (Mathers et al., 2008). Countries 
such as Australia and New Zealand have achieved prevalence rates of HIV below 5% 
whereas in areas such China, Vietnam, Russia and Ukraine the prevalence of HIV infection is 
over 50% (IHRA, 2012). The most current data indicates that prevalence of HIV infection 
among injecting drug users in EU member states ranges from less than 1% up to 60% (Irish 
Focal Point, 2011. Within these countries, a steady decline in HIV prevalence rates has been 
documented among IDUs. Since 2004, a 44% reduction in the number of new HIV diagnoses 
among IDUs has been charted (Pharris et al., 2011). While much of the national prevalence 
data across Europe indicates a declining level of HIV infection among IDUs, certain regions 
such as Portugal, Italy, Spain and Eastern Europe have retained higher rates. Major outbreaks 
of HIV were documented in Estonia, Latvia and Lithuania in the early 2000s leading to a 
rapid elevation in HIV levels across the EU. Even within the past year, outbreaks of HIV 
have been documented in Greece and Romania (EMCDDA/ECDC, 2011).  
A number of studies conducted in an Irish context have endeavoured to extrapolate the 
prevalence of HIV among IDUs. Johnson and colleagues (1994) research a cohort of 
attendees at a Dublin needle exchange and found prevalence of HIV antibodies was 14.8%. 
Prevalence estimates among IDUs in drug treatment settings range from 11% (Grogan et al., 
2005) up to 17% (Fitzgerald, Barry, O’Sullivan, & Thornton, 2001). Studies among injectors 
in prison settings have found prevalence rate s of 3.5% (Allwright et al., 2000) and 5.8% 
(Long et al., 2001). On a national level for Ireland, the most recent data from the HPSC 
mirror the declining trends observed across the majority of Europe, showing a decrease of 
new cases of HIV among IDUs every year from 2006-2010. As of 2010 there were 5700 
cases of HIV, with around 26% of these cases reasoned to have stemmed from injecting drug 
use (O'Donnell, Jackson, Moran, & O'Hora, A2011). The decline in overall HIV rates 
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presents strong evidence that the harm reduction interventions such as needle exchange 
programmes and opioid substitution therapy, implemented during the 1990s have been 
successful in stemming the tide of HIV. However, HIV remains a constant threat as witnessed 
with the outbreaks during the early 2000s, which saw a rapid spread of the virus among IDUs 
and a consequent establishment of high HIV prevalence levels. 
2.4.2. Hepatitis C. Acute Hepatitis C usually presents as asymptomatic. While a fifth 
of acute cases of Hepatitis C will spontaneously clear, four-fifths will progress to chronic 
infection and up to 20% of these will ultimately lead to cirrhosis, and hepatocellular 
carcinoma (NACD, 2008). The primary route of transmission is parenteral (via injection) 
with infection occurring most commonly through contaminated blood. The majority of 
infections among IDUs worldwide stem from unsafe injecting practices (Cook & Kanaef, 
2008). 
Hepatitis C is the most common infection found among IDUs, with an estimated 10 million 
cases among IDUs worldwide and prevalence rates of over 50% in forty-nine countries or 
territories (Aceijas, & Rhodes, 2007). However, wide variances exist in prevalence between 
regions.  China (1.6 million), USA (1.5 million) and Russia (1.3 million) show the highest 
populations of IDUs living with Hepatitis C (Nelson et al., 2011). The ECDC and EMDDA 
report that an estimated 1 million IDUs in Europe are living with HCV, with prevalence rates 
among IDUs across Europe ranging from 22%-83% (ECMDDA, 2012). 
Despite the increased transmission efficiency of viral hepatitis, it has received much less 
research attention than HIV (Cook & Kanaef, 2008). This is particularly true in Ireland where 
knowledge surrounding the epidemiology of Hepatitis C is severely limited. Recent research 
has estimated that as of 2009, there are 10,000 cases of diagnosed Hepatitis C in Ireland, with 
drug use considered to be the main risk factor of infection in 80% of cases (Thornton et al., 
2011). This would suggest there are at least 8,000 current and former drug users living with 
Hepatitis C in Ireland. There is also reasoned to be a large amount of undiagnosed cases 
which would elevate this figure further. Research among IDUs attending drug treatment 
services in Ireland have demonstrated prevalence rates ranging from 52.1% up to 72% 
(O’Sullivan, 2004). High rates have been found among drug injecting prison entrants and 
inmates ranging from 71.7% - 81.3% (Allwright et al., 2000; Long et al., 2001).  
2.4.3. Hepatitis B. When infected, the hepatitis B virus is present in blood, semen, 
vaginal fluids and saliva. Similar to HIV, the main routes for transmission are through 
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contaminated blood, mother to foetus, and sexual interaction (Long, 2006). Chronic infection 
occurs in approximately 1-10% of adult cases of Hepatitis B and 15-40% of these will result 
in cirrhosis, liver failure, or hepatocellular carcinoma (Te & Jensen, 2010). The health 
consequences of Hepatitis B are similar to Hepatitis C in that it may lead to cirrhosis and 
cancer of the liver. However, unlike HIV or Hepatitis C, Hepatitis B is a vaccine-preventable 
disease. 
Research suggests that approximately 1.2 million IDUs worldwide are infected with Hepatitis 
B (Nelson, et al., 2011). Again, there is substantial variability in prevalence across countries 
and regions, with east and Southeast Asia showing the highest levels. In research relating to 
prevalence, there is an important distinction made between two markers of the infection. 
Hepatitis B surface antigen (HBsAG) is indicative of chronic infection, whereas hepatitis B 
core antigen (anti-HBc) points to whether the individual has or has ever had the virus (Long, 
2006). Studies conducted with a sample attending Irish drug treatment services have reported 
prevalence figures of 28.1% for anti-HBc and 5.1% for HBsAg (Fitzgerald et al., 2001). In 
Irish prison settings, research indicates that 18.5% of inmates (Allwright, 2000) and 17.9% of 
entrants (Long et al., 2001) tested positive for anti-HBc.  There has been no research 
conducted concerning Hepatitis B status in needle exchanges in Ireland. Long (2006) states 
that prevalence among IDUs in Ireland has remained lower than expected, which may be 
attributable to the relatively small prospect of chronic infection and the vaccination 
programmes that operate in Irish drug treatment services and prisons.  
2.4.4. Co-infection. In addition to being at increased risk for acquiring the 
aforementioned viruses individually, IDUs also face the risk of contracting more than one of 
these viruses. Co-infection with HIV and HCV is particularly common among IDUs (IHRA, 
2008) and presents even more potent health implications. Studies have shown that persons 
co-infected with HIV and HCV show an increased risk of hepatic disease. HIV infection has 
a detrimental effect on the outcome of Hepatitis C, with co-infection accelerating the 
progression to cirrhosis (Di Martino et al., 2001). Co-infection also leads to an earlier onset 
of hepatocelluar carcinoma (Soriano et al., 2002). In addition to this bleak prognosis, co-
infection also complicates the efficacy of the treatment of HIV (Rhodes et al., 2006b) and the 
presence of Hepatitis C virus increases the risk of progression to AIDs (Long, 2006). End-
stage liver disease is a major cause of death among individuals who are co-infected with HIV 
and hepatitis C (WHO, 2006a).  
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Although co-infection with HIV and HBV appears to be less common, similar health 
consequences are apparent, with co-infection accelerating the natural course of Hepatitis B 
related liver disease (DiMartino et al., 2001) and leading to a much higher likelihood of 
developing chronic Hepatitis B  (Gatanaga, 2000). Risk of liver-related mortality has been 
found to be 17 times more likely for men who are co-infected with HBV and HIV compared 
to those mono-infected with HBV (Thio, 2002).  
2.5. Injecting Risk Behaviour 
2.5.1. Injecting risk behaviour. Injecting drug users face the prospect of a number of 
associated health consequences. Drug-related overdoses contribute to high mortality rates 
among IDUs, while BBVs present a range of acute health conditions and chronic illnesses. 
The injecting process also puts users at risk of acquiring bacterial infections such as 
septicemia and endocarditis, and may cause  trauma to the skin, veins and soft tissue which in 
turn can lead to abscesses, cellulitis and vein collapse. 
As previously outlined, IDUs represent a high-risk group in relation to BBVs. The link 
between needle sharing and virus transmission has long been established, and is reasoned to 
be the primary factor in the spread of HIV, HBV, and HCV among IDUs.  Considering the 
direct contact with blood, needles and syringes carry the most significant threat of becoming 
contaminated. There is general consensus that needle exchange programmes have lead to the 
operative prevention and containment of HIV (Wodak & Cooney, 2004). While at first 
glance, the minimal spread of HIV prevalence among IDUs may seem to herald the success 
of needle exchange programmes in preventing viral transmission, Ashton (2003; pp 4) 
describes this as ‘false reassurance”. Although HIV rates may have remained steady, research 
over the past decade has documented that in spite of the increased accessibility and 
availability of sterile needles and syringes in developed countries, the rates of HCV 
transmission among IDUs continues to rise significantly (Vickerman, Martin, & Hickman, 
2012). 
In light of the divergence between HCV and HIV prevalence, research focus has shifted to 
investigation of the potential sources of this disparity. The characteristics of Hepatitis C make 
it much more difficult to control than HIV due to a number of factors including higher 
prevalence rates, higher mutation and replication rates, and higher concentration in blood 
than HIV (Franciscus, 2011). In injecting drug use terms, when a used needle is shared, the 
likelihood of HCV transmission is 150-800 times higher than the risk of HIV transmission 
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(Crofts, Aitken, & Kaldor, 1999). Considering the increased transmission efficiency of 
Hepatitis C, the role of sharing injecting paraphernalia as an auxiliary source of virus 
infection has received elevated levels of research attention. Research conducted in laboratory 
settings has demonstrated that the Hepatitis C virus can potentially be transmitted through 
paraphernalia sharing as contamination was evidenced on 67% of swabs, 40% of filters, 33% 
of water samples, and 25% of spoons, in a sample collected from injecting sites (Crofts, 
Caruana, Bowden, & Kerger, 2000). Although sharing of paraphernalia is considered to be an 
indirect form of sharing when compared with needle/syringe sharing, the relativity lower 
efficiency of virus transmission may be somewhat offset by the higher incidence with which 
sharing in this form occurs (Bennett, Velleman, Barter, & Bradbury, 2000). 
2.5.2. The injecting process, paraphernalia use and associated risks. Injecting 
drug use involves multiple processes and requires a range of equipment. Many commonly 
used drugs which are consumed by IDUs do not arrive in injectable forms. In order to prepare 
drugs which come in solid (e.g. crack cocaine, black tar heroin), powder (cocaine, white 
heroin) or tablet (e.g. benzodiazepines) form, a cooker is often used to mix these drugs with 
water and acidifiers to manufacture a solute, which may then be heated to create a solution 
with the appropriate consistency for injection. The ‘cooking’ process may require mixing 
with acidifiers to create a salt, which is then added to water to produce a solution. Research 
suggests that sharing of cookers is implicated in transmission of both Hepatitis C (Crofts et 
al., 2000) and HIV (Shah et al., 1996). Cookers appear to be the most prominently shared 
constituents of drug paraphernalia (Leonard et al., 2005; Thorpe et al., 2002; Needle et al,. 
1998) and have also been observed to be re-used for longer periods than other drug 
paraphernalia (Clatts, Heimer & Abdala, 1999). Furthermore, cookers are often used 
communally, particularly when injecting occurs within a social network of IDUs   (Taylor, 
Fleming, Rutherford, & Goldberg, 2004). Even amongst IDUs who use their own sterile 
needle/syringe, there is still the tendency to share a communal cooker (Hunter et al., 1995). 
Reports of sharing of water ranges from 9-75% (e.g. Leonard et al., 2005, Hunter et al., 1995, 
Koester, Booth, & Wiebel, 1990). Virus transmission risks are presented when water is 
shared as multiple IDUs may place previously used needles in to communal water or rinse 
equipment with communal water (Thorpe et al., 2002). 
Once the solution has been “cooked”, IDUs commonly use filters to remove impurities from 
drug solutions and to inhibit the transfer of insoluble particles in to the blood stream. 
Research suggests that sharing of filters is implicated in transmission of both HCV (Crofts et 
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al., 2000) and HIV (Shah et al., 1996). High frequencies of sharing of filters have been 
reported, ranging from 50-77% among IDUs (Huo, Bailey, Garfein, & Ouellet, 2005; Needle 
et al,. 1998). Anecdotal reports also suggest that IDUs may be under the misconception that 
filters retain significant amounts of the active drug compound, and therefore, are reluctant to 
filtrate, or are encouraged to re-use, share, or sell used filters (Bourgois & Schonberg, 2009).  
Once prepared, the drug solution may oftentimes be divided among several IDUs. Equal 
sharing among parties may be achieved through various methods. Popular modes of 
distribution include “frontloading”, whereby the needle attachment will be removed from one 
syringe and then transferred through this hole from the needle of another syringe, and 
“backloading”, whereby the plunger will be removed from one syringe and then drugs will be 
inserted through the back of this syringe from the needle of another syringe. Considering that 
frontloading and backloading involve transferring the drug solution from one syringe through 
a needle to another syringe, there is the risk of also transferring blood-borne pathogens (Jose 
et al., 1993). 
Injection will usually occur in the arm, hand, neck, groin, leg, or foot. A number of potential 
physical health consequences are presented by choice of injection site. Frequent injection in 
to the same site is associated with damage to the vascular structure due to blood clots which 
inflame the vein, and can cause veins to harden and narrow which eventually renders them 
unusable for injection (Maliphant & Scott, 2005). Although all injecting sites carry risks, the 
risk involved in injecting in to the groin or neck is considerably higher. Veins in these sites 
are larger and therefore any damage incurred may result in serious circulatory problems and 
an increased risk of life threatening infections such as endocarditis (Darke, Ross, & Kaye, 
2001). Injection in to the groin is associated with higher risk of deep vein thrombosis, leg 
ulcers and vascular insufficiency. Furthermore, the close proximity of the femoral vein in the 
groin to the femoral artery and nerve also lead to increased morbidity and mortality risk 
(Woodburn & Murie, 1996). Injection can either be administered by the individual 
themselves or by another party. Receiving injections from another IDU is a common practice 
among recent initiates in to drug use (Crofts, Louie, Rosenthal, & Jolley, 1996), whereas 
established drug users are more likely to inject themselves (Cox & Lawless, 2000). 
The geographical location of where injecting occurs, may also influence the level of risk. 
Injecting in public places as opposed to a private domain, has been found to be associated 
18 
 
with higher levels of risk including overdose, unsafe injecting practices and vascular damage, 
and may also mean the improper disposal of needles (Darke et al., 2001). 
2.5.3. The social context of injecting risk behaviour. A number of authors (e.g. 
NACD, 2008; Ashton, 2003; Rhodes, 2002; Bennet et al., 2000) have noted that the social 
aspect of drug use adds a layer of complexity to understanding and influencing risk-taking 
behaviours. Bennet and colleagues (2000) state that the sequence of acquiring and injecting 
drugs involves a host of processes, and that the course of attaining money for drugs, 
purchasing drugs, obtaining injecting equipment, drug preparation, and injection will often 
require several people to collaborate within the chain of this procession. IDUs often operate 
in networks which have developed embedded social norms. Accordingly, sharing of needles 
and equipment may be partially tied to the implicit culture of such networks, where custom, 
etiquette and trust can be the primary determinants of behaviour (Rhodes, 2002). Thus, while 
the provision of sterile equipment and paraphernalia supplies the means, and health 
promotion offers an understanding, they do not directly address the ecological context in 
which drug use occurs. Modification of individual behaviour is therefore unlikely to 
influence the entire gamut of elements which shape injecting risk behaviour (Rhodes et al., 
2005).  
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3. Methodology 
3.1. Research Instrument 
At the outset of the research project, a literature review was conducted to explore 
measurement options (e.g. Teesson et al., 2000) and examine assessment instruments used in 
previous studies relating to drug use (e.g. Gannon, McKeganey, & Hay, 2011). Using 
evidence from past research and insight provided by members of the Health Promotion staff, 
the research team identified four main domains which were to be investigated in the present 
study: 
 Socio-demographic characteristics 
 Substance use 
 Injecting risk behaviour 
 BBV status and treatment 
Consequently, a multi-dimensional research instrument termed the ‘Merchants Quay Health 
Promotion Unit Questionnaire’ was developed, which was based on a number of widely used, 
reliable and valid instruments such as the Treatment Outcomes Profile (TOP; Marsden et al., 
2008) and the Maudsley Addiction Profile (MAP; Marsden et al., 1997), along with 
additional items which were fashioned specifically for the present study. The questionnaire 
relied on self-report. Previous findings have indicated that self-report is a reliable and valid 
method of data collection within the domain of substance misuse and associated behaviours 
(Darke, 1998; Del Boca & Noll, 2002). 
The ‘Socio-demographic characteristics’ section included gender, date of birth, nationality, 
county of residence and housing status. These items were included in the attempt to gain a 
profile of the client base currently attending the Health Promotion Unit at Merchants Quay 
Ireland and to juxtapose the present circumstances of clients with past research and anecdotal 
reports.  Housing status was considered to be a particularly relevant factor as Merchants 
Quay Ireland provides services for both drug users and homeless persons. Therefore, it was 
anticipated that there may be significant overlap between the client bases of the two services. 
This section asked participants where they were currently residing (in the last 7 days) and 
presented common categories of housing status adapted from the Counted In, 2008 
(Homeless Agency, 2008) survey which provided a comprehensive analysis of homelessness 
in Dublin. 
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The ‘Substance Use’ section examined a number of variables regarding commonly used 
substances (heroin, methadone, benzodiazepines, alcohol, mephedrone, cocaine, crack, 
cannabis, amphetamines and steroids) including  the average amount and price of substances 
used per day and the number of days substances were used  in the past week and the past 4 
weeks. The route of administration for each substance was also asked. Questions relating to 
methadone and benzodiazepine use included the option for prescription or illicit. Questions 
relating to benzodiazepine and steroid use included the option to state what types of these 
substances were being used. This section was adapted from the Treatment Outcomes Profile 
(TOP) which is an instrument designed by the National Treatment Agency for Substance 
Misuse (NTA) for monitoring recent substance use treatment and is utilised throughout the 
national drug treatment system in England. 
The ‘Injecting risk-behaviour’ section presented questions relating to a range of behaviours 
which have been identified by past research as risk factors for the transmission of BBVs. 
Participants were firstly asked if they were currently injecting substances. If they were 
injecting substances, they were asked a range of questions relating to sharing of equipment 
and paraphernalia, frequency of injecting, main injecting site and social injecting 
environment.  
The ‘Blood-borne Viruses’ section asked questions concerning Hepatitis B, Hepatitis C and 
HIV. Participants were asked whether they had ever been tested for each of the BBVs, the 
date of last testing, and if they had been tested, what the outcome of the test was. If the 
participant reported that they had tested positive, they were asked whether they were 
receiving treatment, and if not, what the reason for not receiving treatment was.  
3.2. Pilot study 
A one day pilot study was conducted in June 2012.The sample for the pilot study consisted of 
44 participants presenting to the health promotion unit at Merchants Quay Ireland, 36 Males, 
3 Females, 5 Missing Data (age range 21-55 years, M=35.02, SD=7.29).  
The aim of the pilot study was to test all elements involved in the research process. As a 
result of the pilot phase, the questionnaire was amended in response to issues highlighted by 
workers engaged in data collection, and in reaction to participant answers. The layout of the 
questionnaire was adapted to allow data collectors more space to record participants replies, 
questions were reworded to minimise differential interpretations and additional options were 
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included in sections which involved “tick box” answers. Workers were provided with further 
one-to-one training in questionnaire administration, particularly with regard to the substance 
use section. In combination, the changes to the questionnaire and the additional training 
provided more consistent, reliable and accurate data collection.  
The pilot phase also facilitated examination of the logistical concerns in conducting research 
within a busy health promotion unit. Time for completion for the questionnaire was 
approximately 5-10 minutes. Consequently, this periodically created a backlog in the health 
promotion unit. During the main phase of data collection, additional staff were assigned to 
the health promotion unit to resolve this issue. Furthermore, the pilot study afforded the 
research team the opportunity to explore and refine data management and analysis 
procedures. 
3.3. Data Collection 
The research was conducted on a one-to-one basis in the needle exchange and safer injecting 
departments of the health promotion unit in Merchants Quay Ireland. Data collection was 
conducted by the staff working within these departments who had undergone a 
comprehensive training programme. Participants were given an overview of the nature and 
purpose of the research and the content of the questionnaire. These details were outlined in an 
information sheet, which staff discussed with participants prior to requesting consent. If 
consent was given, the Merchants Quay Health Promotion Unit Questionnaire was then 
administered on paper. Health Promotion workers filled out the questionnaire based on the 
participants’ responses. It was then documented on the internal database that the participant 
had completed the questionnaire so as to avoid repeated administrations. 
3.4. Data Management 
3.4.1. Data quality control. Data was collected during the opening hours of the 
health promotion unit. Thus, there were two collection periods each day; 09:45-13:00 
and 13:45-16:30. The research team was on-site at all times and met with data 
collectors at regular intervals during each collection period. At the end of each 
collection period, the research team met with staff to examine completed 
questionnaires and address any difficulties.  
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3.4.2. Data protection. All data collected was anonymous, with participants’ date of 
birth being the only potentially identifiable information. Hard copy versions of the 
completed questionnaires were stored in a file in a locked filling cabinet. Research 
databases were password protected with access limited to the lead researcher.  
 
3.4.3. Data preparation. Questionnaires were examined at the end of each day to 
examine consistency and validity. Missing responses were identified and coded. The 
results presented herein are adjusted for these missing data. The internal database was 
also monitored to ensure that it had been recorded that participants had completed the 
questionnaire.  
 
3.4.4. Data analysis. Data from completed questionnaires were entered in to a 
Microsoft Access database. Microsoft Access was chosen as a data entry tool as it 
allows users to build a template database similar in structure to the questionnaire and 
therefore, ease data entry and minimise the risk of data entry errors. After data entry 
was complete, appropriate statistical data analysis was conducted using SPSS. 
 
3.5. Ethical Considerations 
Due to the nature of the participants and the content of the questionnaire, a number of ethical 
issues presented. Although clients were all over the age of 18, they represented a vulnerable 
group. Health promotion workers were given training prior to starting the data collection 
process, which included being made aware of the nature and purpose of the study, coaching 
on questionnaire administration, how to collect information in a sensitive manner and the 
protocol for referral in to aftercare services. Workers were also supported during the data 
collection process to ensure resolution of any unanticipated ethical issues. Before the 
participants provided data, every attempt was made to ensure that they fully understood the 
basis of the study and were voluntarily willing to participate. Given that the questionnaire 
was administered while participants were availing of the needle exchange service, it was 
explicitly stated that there would be no negative consequences of non-participation and that 
the service would be available to clients regardless of whether they consented or declined. A 
number of steps were taken to ensure that adequate aftercare was offered to the participants. 
Clients who wished to get tested or treated for BBVs were directed to on-site services or 
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alternative services which Merchants Quay had linked with. An on-site counselling service 
was made available to participants in case any distress ensued from completing the 
questionnaire. 
3.6. Limitations of the Study 
Information collected in the present study was based on participants’ self-reports. Although 
this method has been found to be a reliable and valid method of collecting data, there remains 
debate regarding the accuracy of self-report. Despite these concerns, self-report is a feature of 
the majority of research surrounding health and presents the most comprehensive form of 
gathering data regarding  frequency, amount and pattern of drug use and associated variables 
(Bell, 1998). That being said, the findings for sharing of injecting equipment and 
paraphernalia in the present study were incongruous with results from previous research. It 
was felt that the context in which the data collection took place may have influenced 
participants’ responses. Data were collected while participants were attending a service which 
provides sterile injecting equipment and education regarding the risks of sharing. Therefore, 
participants may have been reluctant to respond that they were participating in behaviours 
which were in direct conflict with the objectives of the service they were engaged with. 
Findings concerning BBVs should also be interpreted with caution as results were not based 
on serological testing. However, while self-reported BBV status is not a measure of true 
prevalence, it does provide a useful gauge of levels and trends (Hamers & Downs, 2004).  
An additional issue which may have impacted accuracy of results was the nature of 
participants. Participants were current drug users and at the time of data collection may have 
been experiencing symptoms such as opiate withdrawal, weariness or low mood which may 
have affected ability to accurately recall patterns of behaviour. As suggested by a number of 
authors (e.g. Del Boca & Noll, 2002; Comiskey et al., 2009), the questionnaire was structured 
around specific time periods to reduce the potential influence of recall bias. No data from 
clients who were under the influence of drugs were included.  
The study relied on members of Health Promotion Unit for data collection. Staff had varying 
levels of experience and skill in interacting with clients and structured interviewing. In the 
attempt to minimise this limitation, comprehensive training was provided for questionnaire 
administrators. 
 
24 
 
4. Results 
4.1. Descriptive Statistics 
Table 1 below shows the descriptive statistics for the total sample and the descriptive 
statistics for males and females. A total of 338 participants took part in the study. The age of 
participants ranged from 20 to 59 years (M = 33.86, SD = 7.51). The sample consisted of 290 
males (85.80%) and 48 females (14.20%), showing a gender ratio of approximately 6:1. The 
age of male participants ranged from 20 to 59 years (M = 34.09, SD = 7.13).The age of 
female participants ranged from 21 to 47 years (M = 32.48, SD = 6.76). 
Table 1: Descriptive statistics for the total sample, males and females 
  Total Sample Males Females 
Participants (N)  338 290 48 
Mean (age)  33.86 34.09 32.48 
Median (age)  33  33 33 
Std. Deviation (age)  7.51 7.60 6.76 
Range (age)  20‐59 20‐59 21‐47 
 
Table 2 below provides a breakdown of the age profile for the total sample, males and 
females. The highest proportion of participants (n=91; 27%) fell in to the age range from 30-
34 years. This age range showed the highest numbers of both male (n=78; 27%) and female 
(n=13; 27%) participants.   
Table 2: Age profile for the total sample, males and females 
 Total Sample (N=335) 
Males 
(n=287) 
Females 
(n=48) 
 n % n % n % 
20-24 yrs 29 9 21 7 8 17 
25-29 yrs 73 22 65 23 8 17 
30-34 yrs 91 27 78 27 13 27 
35-39 yrs 69 21 57 20 12 25 
40-44 yrs 43 13 39 14 4 8 
45+ yrs 30 9 27 9 3 6 
*Missing Observations=3 
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4.2. Socio-demographic characteristics  
4.2.1. Nationality. The participant group was made up of 19 different nationalities. 
Table 3 illustrates that a large majority of participants were Irish nationals (n=297). EU12 
nationals were comprised of Estonian (n=1), Latvian (n=8), Lithuanian (n=4), Polish (n=4), 
Romanian (n=2) and Slovenian (n=1). Other nationalities included American (n=1), Brazilian 
(n=1), English (n=6), Georgian (n=2), Indian (n=1), Italian (n=1), Mauritian (n=1), Moldovan 
(n=1), Moroccan (n=1), Portuguese (n=1), Russian (n=3) and Scottish (n=1). 
Table 3: Nationality 
 n % 
Irish Nationals  297 88 
EU12 Nationals 20 6 
Other 20 6 
Total 337 100 
*Missing Observations=1 
4.2.2. County of residence. Table 4 highlights that the majority of participants 
resided in Dublin (n=302). Counties of residence from the rest of Leinster included Carlow 
(n=1), Kildare (n=4), Louth (n=3), Meath (n=3), Offaly (n=2) and Wexford (n=5). Counties 
of residence from Munster included Cork (n=2), Limerick (n=1), Tipperary (n=2) and 
Waterford (n=1). Counties of residence from Connaught included Galway (n=1) and 
Roscommon (n=1). Donegal (n=2) was the only county of residence from Ulster reported. 
Table 4: County of residence 
 n % 
Dublin 302 91 
Rest of Leinster 18 5 
Munster 6 2 
Connaght 2 1 
Ulster 2 1 
Total 330 100 
*Missing Observations=8 
4.2.3. Housing status. Table 5 illustrates the housing status of participants during the 
past 7 days. The largest category of housing status identified in the study was own/rented 
home, with approximately 47% of participants falling under this category (n=160). Just over 
a fifth of participants had resided with family/friends in the past week (n=74; 21%) and a 
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similar proportion had resided in Emergency Accommodation in the past week (n=67, 20%). 
Less than 5% of participants reported sleeping rough in the past week (n=15; 4%) with 
similar trends reported in the categories of Supported Temporary Accommodation (n=12; 
4%) and long-term supported housing (n=11; 3%). One participant reported residing in a 
category which was not included in the questionnaire (long-term hostel). Two participants 
reported residing in more than one category during the past 7 days - Emergency 
Accommodation/Sleeping Rough (n=1) and staying with friends/family/Sleeping rough 
(n=1).  
Table 5: Housing status over the past week 
 n % 
Own/Rented home 160 47 
Staying with friends/family 74 22 
Emergency Accommodation 67 20 
Sleeping Rough 15 4 
Supported Temporary Accommodation 12 4 
Long-term supported housing 11 3 
Other 1 1 
*Missing Observations=1 
4.3. Substance Use 
4.3.1. Substance use. Table 6 shows current substance use for the total sample. 
Heroin was the most prevalently used substance amongst the sample with approximately 86% 
of respondents reporting that they had used heroin in the past month (n=290).  Prescribed 
methadone was the next most commonly used substance with just under half of participants 
reporting use of such within the past month (n=167; 49%). Approximately 34% of 
participants (n=109) reported using benzodiazepines in the past month, with 16% of 
participants reporting use of prescribed benzodiazepines (n=49) and 18% of participants 
reporting use of illicit benzodiazepines (n=56). Use of cannabis (n=82; 24%), and alcohol 
(n=74; 22%), was also prevalent within the study population. Steroids (n=25; 7%), cocaine 
(n=21; 6%), mephedrone (n=21; 6%), crack (n=20; 6%), other (n=13; 4%), illicit methadone 
(n=8; 2%) and amphetamines (n=4; 1%) were all used by less than 1 in 10 participants within 
the past month. See Appendix A for a more detailed examination of substance use in the past 
month.  
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Table 6: Substance use over the past month 
Substances Used Total 
 n % 
Heroin 290 86 
Prescribed Methadone 167 49 
Cannabis 82 24 
Alcohol 74 22 
Illicit Benzodiazepines 60 18 
Prescribed Benzodiazepines 53 16 
Steroids 25 7 
Cocaine 21 6 
Mephedrone 21 6 
Crack 20 6 
Other 13 4 
Illicit Methadone 8 2 
Amphetamines 4 1 
 
4.3.2. Substance use by gender. Table 7 outlines current substance use for males and 
females. The data suggested few gender differences in use of heroin, cannabis, alcohol, 
cocaine, crack, or illicit methadone. Proportionally higher levels of prescribed methadone use 
were reported amongst females in comparison to males (73% v 46%). Similar gender trends 
were discovered regarding illicit and prescribed benzodiazepines with a higher proportion of 
females reporting use of such. For females, use of illicit benzodiazepines was higher than use 
of cannabis or alcohol which showed a difference in substance use tendencies when 
compared to the male sample. Comparable patterns were observed for females in relation to 
use of ‘other’ substances (primarily anti-depressants) and use of mephedrone. No females 
reported using steroids in the past month whereas 9% of males reported use. Likewise, no 
females reported current use of amphetamines while 1% of males reported use.  
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Table 7: Substance use by gender over the past month 
Substances Used Males (n=290) Females (n=48) 
 n % n % 
Heroin 249 86 41 85 
Prescribed Methadone 132 46 35 73 
Cannabis 71 24 11 23 
Alcohol 63 22 11 23 
Illicit Benzodiazepines 48 17 12 25 
Prescribed Benzodiazepines 42 14 11 23 
Steroids 25 9 0 0 
Cocaine 17 6 4 8 
Mephedrone 16 6 5 10 
Crack 16 6 4 8 
Other 7 2 6 13 
Illicit Methadone 7 2 1 2 
Amphetamines  4 1 0 0 
 
4.3.3. Poly-drug use. Table 8 depicts current the number of substances currently 
being used by participants. In the present study, poly-drug use was defined as using two or 
more substances concurrently, and includes both legal and illegal drugs. A large majority of 
participants were poly-substances users (n=252; 75%). Approximately 30% of the sample 
reported using two substances within the past month (n=102), 25% reported using three 
substances (n=85), 12% reported using four substances (n=40) and 6% reported using five 
substances (n=20). Less than 2% of participants reported use of more than 5 substances 
within the past month (n=5).  
Table 8: Number of substances used over the past month 
No. of Substances Used n % 
1 86 25 
2 102 30 
3 85 25 
4 40 12 
5 20 6 
6 4 1 
7 1 >1 
Total 338 100 
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4.3.4 Single substance use. As outlined above, one-quarter of the sample reported use 
of a single substance in the past month. Table 9 illustrates that the majority of participants, 
who used one substance during the past month, used heroin only (n=64; 78%). Steroids were 
the next most prevalent substance used by non-poly drug users (n=15; 17%).   
Table 9: Single Substance Use over the past month 
Substance Used n % 
Heroin Only  67 78 
Steroids Only 15 17 
Other Only 2 2 
Amphetamines Only 1 1 
Methadone (px) Only 1 1 
Total 86 100 
 
4.3.5. Poly-drug combinations using two substances. As presented in Table 8, 
approximately 30% of participants reported current use of two drugs. Table 10 shows that the 
most frequent combination of poly-drug use involving two substances was heroin and 
methadone (n=49; 48%). Use of heroin in combination with cannabis (n=12; 13%), 
benzodiazepines (n=10; 10%) and alcohol (n=10; 10%) was also found to be prevalent. The 
proportion of use of any other combinations of two substances was lower than 5%.   
Table 10: Poly-drug combinations using two substances 
Substances Used n % 
Heroin, Methadone  49 48 
Heroin, Cannabis 13 13 
Heroin, Benzos 10 10 
Heroin, Alcohol  10 10 
 
4.3.6. Poly-drug combinations using three substances. Table 8 highlighted that just 
over a quarter of participants reported using 3 substances in the past month. Table 11 
indicates that concurrent use of a combination of heroin, methadone, and benzodiazepines 
(n=26; 30%) was the most prevalent form of poly-drug use in this category. Heroin and 
methadone were also commonly used in conjunction with cannabis (n=12; 13%), and alcohol 
(n=12; 13%). A variety of other combinations involving three substances were being used by 
participants, with the majority involving use of heroin and two other substances.  
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Table 11: Poly-drug combinations using 3 substances 
 
4.3.7. Prescribed methadone and other drug use. Table 12 below highlights the use 
of prescribed methadone in conjunction with other substances. In total, just over half of the 
sample reported use of prescribed methadone in the past month (n=167; 49%). Only one 
participant reported use of prescribed methadone only, highlighting that almost all 
participants who used prescribed methadone were also using other substances. Almost 9 out 
of 10 users of prescribed methadone were also using heroin.  
Table 12: Prescribed methadone and other drug use 
 Total 
 n % 
Heroin 148 89 
Prescribed Benzodiazepines 46 28 
Cannabis 46 28 
Alcohol 41 25 
Illicit Benzodiazepines 35 21 
Crack 16 10 
Mephedrone 13 8 
Other 7 4 
Steroids 2 1 
Amphetamines 1 1 
 
Given the large proportion of participants found to be using heroin and methadone 
concurrently within the past month, a further analysis was conducted (see Appendix A, Table 
29). Inspection of the data suggested that in comparison to those who used heroin as well as 
prescribed/illicit methadone, participants who used heroin and no methadone consumed 
higher average amounts of heroin per day, spent more money on heroin per day, and used 
heroin the most days in the past month.  
Substances Used n % 
Heroin, Methadone, Benzos 26 30 
Heroin, Methadone, Cannabis 12 14 
Heroin, Methadone, Alcohol 12 14 
Heroin, Cannabis, Benzos 7 8 
Heroin, Cannabis, Alcohol 6 7 
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4.4. Injecting Risk Behaviour  
4.4.1. Frequency of injection. Just over 97% of participants reported that they were 
currently injecting substances (n=329). Those who were not currently injecting reported 
ingestion, smoking and snorting as their routes of drug administration. The amount of times 
that participants injected substances in the past week ranged from 0-70, with participants 
injecting an average of just over 10 times in the last week (M=10.19, SD=11.78). Table 13 
displays participants’ reported frequency of injection in the past week. The majority of 
participants (42%) reported injecting substances between 1-5 times in the past week.  
Table 13: Frequency of injection over the past week 
 n % 
0 times 23 7 
1-5 times 132 42 
6-15 times 99 31 
16-25 times 28 9 
26-35 times 22 7 
More than 35 times 14 4 
Total 318 100 
*Missing Observations=5 
4.4.2. Main injecting sites. Table 14 illustrates the main injecting sites currently used 
by participants. Approximately a quarter of the sample (n=81) reported currently using more 
than one main injecting site. The most prevalent injecting site reported was arms, with 
approximately 55% of participants using their arms for injecting (n=174). Almost a third of 
participants (n=98) reported injecting in either the groin or the neck.  
Table 14: Main injecting sites over the past month 
Injecting Site n % 
Arms 174 55 
Groin 91 29 
Legs 28 9 
Hands 17 5 
Feet 14 4 
Buttocks 13 4 
Neck 7 2 
Other 7 2 
*Missing Observations=23 
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4.4.3. Sharing of injecting equipment and paraphernalia. Almost three-quarters of 
respondents reported that they had not shared injecting equipment or paraphernalia in the past 
month (n=232; 73%). Just over a quarter of respondents reported sharing at least one piece of 
injecting equipment in the past month. Table 15 illustrates that the most commonly shared 
elements were water, which was reportedly shared by approximately 13% of respondents, and 
tourniquets, which were reportedly shared by just over 12% of respondents.  
Table 15: Sharing of injecting equipment and paraphernalia over the last month 
Item shared n % 
Water 43 13 
Tourniquet 39 12 
Syringe 33 10 
Cooker 32 10 
Foil 28 9 
Filter 28 9 
Frontloading 24 8 
Needle 22 7 
Backloading 17 5 
 
4.4.4. Physical injecting environment. Figure 1 overleaf depicts the physical 
injecting environment of participants. Almost 86% of the sample reported that during the past 
week they had generally been injecting in a private domain (n=268) and just over 14% 
indicated that they had generally been injecting in a public area (n=44). 15 participants were 
not currently injecting and 11 participants did not provide a response.  
Figure 1: Physical Injecting Environment
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4.4.5. Social injecting environment. Figure 2 illustrates the social injecting 
environment of participants. Approximately 59% of the sample reported generally injecting 
on their own during the past week (n=184) and almost 41% reported generally injecting with 
other people during the past week (n=126). 15 participants were not currently injecting and 
13 participants did not provide a response.  
Figure 2: Social Injecting Environment 
 
4.4.6. Administration of injection. Figure 3 shows that almost 88% reported being 
generally injected by themselves during the past week (n=274) and just over 12% reported 
being generally injected by another person/s during the past week (n=38). Fifteen participants 
were not currently injecting and eleven participants did not provide a response. 
Figure 3: Administration of Injection 
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4.5. Blood-borne Viruses  
4.5.1. HIV. Table 16 shows the data relating to testing for HIV. Approximately 78% 
of participants had been tested for HIV (n=264). Just over 20% had not been tested (n=69). 
Two participants did not know if they had been tested for HIV. Three participants declined to 
answer any questions relating to HIV.  
Table 16: HIV testing 
 n % 
Tested 264 78 
Not Tested 69 20 
Not known if tested 2 1 
Declined to answer 3 1 
Total 338 100 
 
Table 17 presents the HIV test results of participants. Just over 8% of participants who had 
been tested for HIV had tested positive (n=22), with approximately 89% testing negative 
(n=234). Around 3% of participants did not know the result of their test (n=8).  
Table 17: HIV test results 
 n % 
Positive 22 8 
Negative 234 89 
Unknown 8 3 
Total 264 100 
 
For those who had been tested, length of time since last test ranged from 0-24 years (M=1.62, 
SD=2.69). However 41 participants could not provide an estimate of when they were last 
tested for HIV. Table 18 illustrates that 55% of participants who reported that they were 
negative for HIV had been tested within the past year.   
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Table 18: Length of time since last HIV testing for those who reported negative status 
 n % 
Less than 6 months 91 46 
6-12 months 18 9 
1-2 years 45 23 
2-3 years 19 10 
More than 3 years 25 13 
Total 198 100 
 
Table 19 shows the treatment status of participants who had tested positive for HIV. 
Approximately 45% of those who reported being positive for HIV were receiving treatment 
and 9% were awaiting treatment. Around 46% were not receiving treatment. The reasons 
reported for not receiving treatment were ‘not appropriate for treatment’ (9%; n=2), ‘declined 
treatment’ (5%; n=1), ‘service not offered’ (5%; n=1) and other (14%; n=3) who reported that 
they were ‘afraid to get treatment’ (n=1) and ‘treatment was not needed’ (n=2). Two 
participants did not offer a reason for not receiving treatment.  
Table 19: Treatment for HIV 
 n % 
Receiving treatment 10 45 
Declined treatment 1 5 
Service not offered 1 5 
Not appropriate for treatment 3 14 
Awaiting treatment 2 9 
Other 3 14 
Unknown 2 9 
Total 22 100 
 
4.5.2. Hepatitis C. Table 20 presents the data regarding participants’ testing for 
Hepatitis C. Approximately 82% of participants had been tested  for Hepatitis C (n=274). Just 
over 15% of participants had not been tested (n=55). Six participants did not know if they had 
been tested. Three participants declined to answer any questions relating to Hepatitis C.  
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Table 20: Hepatitis C testing 
 n % 
Tested 278 82 
Not Tested 55 16 
Not known if tested 2 1 
Declined to answer 3 1 
Total 338 100 
 
Table 21 presents the Hepatitis C test results of participants. Approximately 45% of 
participants who had been tested for Hepatitis C had tested positive (n=125), with almost 
51% testing negative (n=140). Around 4% of participants did not know the result of their test 
(n=12). For those who had been tested negative for HCV, length of time since last test ranged 
from 0-24 years (M=1.68, SD=3.16). However forty-four participants could not provide an 
estimate of when they were last tested for Hepatitis C.   
Table 21: Hepatitis C test results 
 n % 
Positive 125 45 
Negative 140 50 
Unknown 13 5 
Total 278 100 
 
Table 22: Length of time since last hepatitis C testing for those who reported negative status 
 n % 
Less than 6 months 32 29 
6-12 months 38 34 
1-2 years 20 18 
2-3 years 8 7 
More than 3 years 14 12 
Total 112 100 
 
Table 23 shows the treatment status of participants who had tested positive for Hepatitis C. 
Eighteen of the participants who had tested positive for Hepatitis C were receiving treatment. 
One hundred and seven participants were not receiving treatment. The reasons reported for 
not receiving treatment were declined treatment (n=9), service not offered (n=16), not 
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appropriate for treatment (n=16), awaiting treatment (n=29), and other (n=21). The other 
reasons reported for not receiving treatment included ‘virus dormant’ (n=10), ‘no contact 
with health service’ (n=2), ‘afraid to get treatment’ (n=1), ‘circumstances’ (n=2), ‘coming off 
methadone first’ (n=1), ‘did not go on treatment as wanted a child’ (n=1), ‘finished treatment 
(n=1), ‘not clean’ (n=1), ‘did not present for treatment’ (n=2). Sixteen participants did not 
offer a reason for not receiving treatment.  
Table 23: Treatment for Hepatitis C 
 n % 
Receiving treatment 18 14 
Declined treatment 9 7 
Service not offered 16 13 
Not appropriate for treatment 16 13 
Awaiting treatment 29 23 
Other 21 17 
Unknown 16 13 
Total 125 100 
 
4.5.3. Hepatitis B. Table 24 presents the data regarding participants’ testing for 
Hepatitis B. Approximately 78% of participants had been tested for Hepatitis B (n=262). 
Almost 21% had not been tested (n=73) and less than 1% did not know if they had been 
tested (n=3). Three participants declined to answer any questions relating to Hepatitis B.  
Table 24: Hepatitis B testing 
 n % 
Tested 263 78 
Not Tested 69 20 
Not known if tested 3 1 
Declined to answer 3 1 
Total 338 100 
 
Table 25 presents the Hepatitis B test results of participants. Almost 5% of participants who 
had been tested for Hepatitis B had tested positive (n=13), with approximately 92% testing 
negative (n=241). Around 3% of participants did not know the result of their test (n=9).  
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Table 25: Hepatitis B test results 
 n % 
Positive 12 5 
Negative 241 92 
Unknown 9 3 
Total 262 100 
 
For those who had been tested negative for HBV, length of time since last test ranged from 0-
24 years (M=2.18, SD=3.80). However thirty-seven of these participants could not provide an 
estimate of when they were last tested for Hepatitis B.   
Table 26: Length of time since last HVB testing for those who reported negative status 
 n % 
Less than 6 months 41 20 
6-12 months 65 32 
1-2 years 45 22 
2-3 years 21 10 
More than 3 years 32 16 
Total 204 100 
 
Table 27 shows the treatment status of participants who had tested positive for Hepatitis B. 2 
of the participants who had tested positive for Hepatitis B were receiving treatment. 10 
participants were not receiving treatment. The reasons reported for not receiving treatment 
were declined treatment (n=2), service not offered (n=1), not appropriate for treatment (n=1), 
awaiting treatment (n=1), and other (n=2) who reported that treatment was not needed.  
Table 27: Treatment for hepatitis B 
 n % 
Receiving treatment 2 17 
Declined treatment 2 17 
Service not offered 1 8 
Not appropriate for treatment 1 8 
Awaiting treatment 4 33 
Other 2 17 
Total 12 100 
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4.5.4. Co-infection. Table 28 illustrates testing across combinations of infections and 
the prevalence of co-infection among participants. Overall 24 participants reported co-
infection with more than one virus. The most prevalently reported co-infection was Hepatitis 
C/HIV (n=15) which accounted for approximately 6% of those who had been tested for both 
infections (n=262). Hep B/Hep C (n=5), which accounted for approximately 3% of those who 
had been tested for both infections (n=262), and Hep B/Hep C/HIV (n=1), which accounted 
for approximately 0.39% of those who had been tested for all three viruses (n=258), were the 
additional co-infections found. Figure 3 summarises the inter-relationships between 
infections among participants.  
Table 28: Testing & co-infection status 
 Tested   Positive Co-infection 
 n % n % 
Hep C/HIV 262 78 15 6 
Hep B/Hep C 262 78 8 3 
Hep B/Hep C/HIV 258 76 1 <1 
 
Figure 4: Inter-relationships between infections 
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5. Discussion  
The age findings in the present study echo a general trend identified across studies which 
have found that the population of Irish opiate users is ageing. The mean and median age 
found in the present study were relatively high in comparison to recent research conducted 
across a variety of drug treatment settings in an Irish context (Comiskey et al., 2009), and 
older research of attendees at a Dublin needle exchange (Johnson et al., 1994). This shift in 
the age profile is noteworthy as older drug injectors are likely to have increasing levels of 
health problems (Kelly et al., 2009), are more likely to be HIV positive (Smyth, Keenan, & 
O’Connor, 1998; Long et al, 2001) and Hepatitis B positive (Long et al., 2001; Allwright et 
al., 2000).  
Research has consistently demonstrated differences in the gender distribution of injecting 
drug users, namely that IDUs are more likely to be male. Previous studies in the context of 
Merchants Quay have observed ratios of approximately 3:1 among new clients (Cox 
&Lawless, 2000). The male to female gender ratio found in the present study is notably 
higher than those found in European and national research. Female injecting drug users have 
been found to be more likely to engage in injecting risk behaviours (Montgomery et al., 
2002) and previous research has identified a number of gender-specific issues in the realm 
drug services. Consequently, a gendered approach to drug services which places particular 
importance on care and support (Poole & Dell, 2005), provision of female counsellors 
(Painter, Riley-Buckley, & Whittington, 2000), support groups (EMCDDA, 2006), childcare 
facilities (Moran, 1999) and integrative service provision with greater collaboration and 
communication between agencies (Comiskey et al., 2009) has been suggested to enhance 
accessibility and utility for female service users.  
Similar issues are evident in relation to migrants, and with the vastly increasing level of 
international migration, migrant health has become a significant global public health issue 
(Ghent, 2008). The majority of participants in the present study were Irish nationals. 
However, the sample consisted of nineteen different nationalities. The transcultural 
competence of health and social services is coming under increasing examination, with the 
growing diversity witnessed amongst service users presenting a number of challenges. The 
literature demonstrates that there are diverse and varied issues and barriers around service 
access and service use among migrants who use drugs services (Fountain, Bashford, & 
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Winters, 2003; Sangster, Shiner, Patel, & Sheikh, 2002), which should be addressed in 
service design.  
Housing status has been identified as a significant variable within the domain of drug use 
(e.g. Lawless & Corr, 2005). Approximately a third of participants in the present study were 
residing in categories which were classified as homeless. Framing these findings within the 
European Typology on Homelessness and Housing Exclusion (ETHOS) utilised in Counted 
In (Homeless Agency, 2008), approximately 7% of participants would be considered 
houseless, and 24% would be considered roofless. Previous research has found high levels of 
sharing of injecting equipment and elevated prevalence of BBVs among homeless drug users 
(Corneil et al., 2006; Rhodes et al., 2006a; Cox & Lawless, 2000), and as such, this group 
represents a particularly at risk group.  
Poly-drug use, including the combination of illicit drugs with alcohol, and sometimes, 
medicines and non-controlled substances, has become the dominant pattern of drug use in 
Europe (EMCDDA, 2011). This pattern was evident in the present study, with prevalence 
rates showing consistency with previous research in an Irish context (Bellerose, Carew, & 
Lyons, 2011; Comiskey et al., 2009). This accumulation of evidence suggests that the 
majority of problem drug users in Ireland are poly-drug users. Though poly-drug use has 
become the rule rather than the exception, the patterns of use across countries are markedly 
divergent (EMCDDA, 2009).  The largest proportion of poly-drug users in the present study 
were currently using two substances, with the most commonly used combinations among this 
group being use of heroin/methadone, heroin/cannabis, heroin/benzodiazepines, and 
heroin/alcohol. Within these trends of poly-drug use noted, the high prevalence of prescribed 
methadone use in combination with heroin and the widespread use of opioids and 
benzodiazepines, are cause for particular concern as concomitant use of these substances 
increases the risk of fatal and non-fatal overdose (EMCDDA, 2009).  
 A further noteworthy feature of the present study was the prevalence of steroid users found 
among participants. Increasing participation in needle exchange programs among steroid 
users has been found internationally (Rich et al., 1999) and more recently, needle exchanges 
based in the UK have witnessed a dramatic rise in the numbers of steroid users presenting  
(Evans-Brown & McVeigh, 2008). Although there are reports of clients who are steroid 
injectors in almost two-thirds of needle exchange services in Ireland (Robinson et al., 2008), 
there has been little published data on this developing trend. Public health initiatives have the 
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propensity to overlook users of performance- and image-enhancing drugs (Larance, 
Degenhardt, Copeland, & Dillion, 2008). Given the furtive nature of use of such substances, 
users are reluctant to seek medical treatment (Dunn, 2002) and thus, the main agencies which 
are likely to maintain regular contact with this group are needle and syringe programmes 
(Larance et al., 2008). Though in general, rates of BBVs and injecting risk behaviour tend to 
be lower among steroid users than other groups of IDUs (Day et al., 2008; Aitken, Delalande 
& Stanton, 2002), they remain at significant risk of physical and psychological harm (Evans-
Brown & McVeigh, 2008).  
Inspection of the findings regarding the injecting behaviours, highlight high levels of unsafe 
practices such as use of only one main injection site and injecting in to either the groin or the 
neck. Frequent injection in to the same site is associated with damage to the vascular 
structure due to blood clots which inflame the vein, and can cause veins to harden and narrow 
which eventually renders them unusable for injection (Maliphant & Scott, 2005). Although 
all injecting sites carry risks, the risk involved in injecting in to the groin or neck is 
considerably higher. Veins in these sites are larger and therefore any damage incurred may 
result in serious circulatory problems and an increased risk of life threatening infections such 
as endocarditis (Darke et al., 2001). Injection in to the groin is associated with higher risk of 
deep vein thrombosis, leg ulcers and vascular insufficiency. The close proximity of the 
femoral vein in the groin to the femoral artery and nerve also lead to increased risk of 
morbidity and mortality (Woodburn & Murie, 1996).  
Previous research within MQI found that only 5% of new clients reported injecting into these 
particularly dangerous sites (Cox & Lawless, 2000). A possible rationale for the disparity in 
findings is that over half the participants in the Cox and Lawless study had been injecting for 
less than a year. Darke and colleagues (2001) detail that the majority of injecting drug users 
usually start their injecting careers by injecting in to the crook of the arm, which moves to 
injection in the forearm, upper arm and hand within four years, progressing to injection in the 
neck feet and leg within 6 years, and finally to the groin, fingers and toes within 10 years.  
Thus, the injecting sites reported in the present study may be representative of a sample of 
IDUs who have had a longer injecting career. Research suggests that IDUs consider the groin 
to be a convenient injection site which is easy to use, quick and less painful with less risk of 
missing the vein. Qualitative narratives suggest that the primary reason for using the groin as 
an injection site is that there are no other ‘convenient’ sites left for injection (Maliphant and 
Scott, 2005).  
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Sharing of needles and syringes has been identified as the overt route of BBV transmission. 
There is also increasing recognition and investigation in to the role of sharing injecting 
paraphernalia as a further mode of transmission. The incidences of sharing reported 
represented substantially lower rates than the majority of previous research. There are a 
number of possible explanations for this inconsistency. Firstly, it may be indicative of the 
success of the health promotion unit in educating service users about the risks involved in 
sharing and providing the means for safer injecting. However the possibility that the context 
in which the data collection took place may have influenced responses should be considered. 
An additional factor is that a quantitative methodology may not be the most appropriate form 
of exploring sharing of equipment as injectors may not be clear on what constitutes ‘sharing’ 
and may not consider indirect sharing of paraphernalia as a form of sharing. Given the large 
variances in reports of frequency of sharing, the heterogeneity of drug using populations, 
differential access to services, and methodological research concerns, it is difficult to 
ascertain a definite portrait of the quantity of users who share paraphernalia. It is clear 
however that despite being in contact with a service which provides access to equipment and 
paraphernalia, and education surrounding the risks of sharing, a proportion of service users 
continue to engage in these risk behaviours.  
While reductions in the prevalence of sharing of injecting equipment and HIV have been 
witnessed throughout the literature, it is important to note the role of social and structural 
contexts in shaping individual injecting risk behaviours (Rhodes, 2002). The proportion of 
those injecting with others, assisted injecting and injecting in public places reported in the 
present study represents a significant amount of injecting drug users who are at elevated risk 
of severe health consequences. Although injecting in the company of others reduces the risk 
of fatal overdose (Hagan et al., 2007), it is also linked to unsafe injecting practices (Taylor et 
al., 2004; Wodak & Crofts, 1996). Receiving an injection administered by another person is 
associated with non-fatal overdose and has been shown to predict elevated levels of sharing 
needles and syringes (Kerr et al., 2007; Kerr et al., 2005). Heightened risk of BBV 
transmission is also correlated with this behaviour as those who receive injections have been 
found to be twice as likely to contract HIV (O’Connell et al., 2005). Fairbairn and colleagues 
(2010) have documented several barriers to self-injection which include lack of injection-
related knowledge and technique and inability to access veins due to long-term injecting. This 
highlights the importance of safer injecting education within harm reduction services 
whereby IDUs can acquire the proficiency for self-injection and the knowledge to minimise 
44 
 
vascular damage. Injecting in public places is also associated with a higher level of risk 
behaviour (e.g. Darke et al., 2001; Klee & Morris, 1995).  
The challenges presented by the social and structural environment of injecting reinforce the 
significance of the pillars upon which the practice of harm reduction is founded. Taylor and 
colleagues (2004) re-emphasise the importance of educating IDUs around the risks involved 
in sharing, particularly with reference to indirect sharing, and the potential for BBV 
transmission at all stages of the injecting process. Providing sterile injecting paraphernalia is 
an important element in minimising the risk of harm. However, while supplying the means 
and the education may help to reduce individual injecting risk behaviour, without 
investigation and intervention in to contextual factors, further progress may be limited. An 
emerging strategy designed to combat such risks is the development of safer injection 
facilities (SIF) which provide amenities for medically supervised drug consumption. Such 
facilities are currently in operation in 62 cities internationally and although evidence broadly 
supports the efficacy of SIFs, they remain a controversial harm reduction approach (Hedrich, 
Kerr, & Dubois-Arber, 2010).  
 
In discussion of the prevalence of BBVs, it should be noted that status was based on self-
report, a proportion of the sample had not been tested previously, and the frequency of testing 
within the past year was low. Thus, the reported prevalence may differ from the true 
prevalence, and in all likelihood, represents a conservative estimate. The prevalence of HIV 
reported indicated a lower rate of infection as compared to previous results from studies 
conducted within Irish needle exchange (Johnson et al., 1994) and drug treatment services 
(O’Sullivan et al., 2004). The reported prevalence is almost an exact match with a study from 
Dorman and colleagues (1997) among a sample of Irish IDUs both in and out of treatment. 
The rates of HIV testing found suggest that access and uptake appears to have improved in 
comparison to findings from previous research (Cox & Lawless, 2000). However a relatively 
high proportion of the sample had not been tested previously. Frequency of testing remains a 
further concern. Considering the high risk of infection among IDUs, it is recommended that 
examination and testing is offered at least once every six to 12 months (ECMDDA, 2010). 
Lack of knowledge of HIV status is problematic for both personal and public health (WHO, 
2010). On the personal level, awareness of positive HIV status affords individuals the 
opportunity to access appropriate treatment, care and support. Early diagnosis and timely 
treatment improves the prognosis of the infection and is associated with reduced morbidity 
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and mortality when compared to those who present later (Palella et al., 1998). In combination 
with early diagnosis, counselling may guide people to reduce risk taking behaviours and 
decrease the threat of HIV transmission to injecting and sexual partners (WHO, 2010; 
ECMDDA, 2010). It is therefore vital to address the deficiencies in access to, and barriers to 
the uptake of, HIV testing. Research surrounding barriers (Obermeyer, & Osborn, 2007; 
Downing et al., 2001) have identified client factors which include a lack of knowledge 
around risk and locations of testing sites, and a fear of the repercussions, and service-related 
factors such as a lack of convenient locations, insufficient communication around offering 
testing, and failure to provide appropriate models of service. Uptake of treatment for those 
who reported being positive for HIV in the present study also appears to be a problematic 
issue. Although IDUs report much higher levels of medical complaints then the general 
population, links with health care services are often fragmented (Saitz, Mulvey, & Samet, 
1997). Models of service suggested to overcome the obstacles faced by IDUs in accessing 
HIV treatment include co-locating HIV primary care and substance dependence treatment 
programmes, and linking primary care to specialist clinics (WHO, 2006b). 
 
The prevalence of Hepatitis C reported is relatively low in relation to previous studies 
conducted with IDUs attending drug treatment in Ireland (Smyth et al., 1998; Cullen, Bury, 
Barry, & O’Kelly, 2000; O’Sullivan, 2004). However, the prevalence is much elevated when 
compared to previous research in Merchants Quay Ireland (Cox & Lawless, 2001). Although 
similar problematic issues are apparent in access, uptake and frequency regarding testing for 
both HIV and Hepatitis C, Hep C does show a slightly higher rate of lifetime testing, and 
testing within the past year, when compared to HIV testing. This may be representative of the 
increasing recognition and response to the epidemic. Screening for Hepatitis C is currently 
offered in drug treatment programmes and prisons in Ireland. While this may reflect a 
positive step, the findings do suggest that there is still considerable work to be done.   
A further concern is the rate of participants who reported being positive for Hepatitis C and 
were not receiving treatment. Studies in an Irish (Cullen et al., 2007) and international 
context (Strathdee et al., 2005; Doab, Treloar, & Dore, 2005) have demonstrated poor levels 
of Hepatitis management among IDUs.  Research points to a large amount of uncertainty 
regarding understanding of Hepatitis C among IDUs, with a lack of effective communication 
of test results and diagnosis a particular concern (Rhodes, Davis, & Judd, 2004). Testing, 
management, and treatment for this group appear to be complex issues and are impacted by a 
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host of variables. Recent qualitative research from Swan and colleagues (2010) examined 
barriers to and facilitators of Hepatitis management in an Irish context, suggesting that 
perceptions surrounding Hepatitis C significantly influenced management of the virus. 
Among many IDUs, HCV was normalised in comparison to HIV, with participants 
perceiving Hepatitis C as a common and relatively benign infection. The absence of overt 
symptoms reinforces the perception that HCV does not significantly impact health, and 
consequently, reduces the perceived need for medical attention. In brief, Hepatitis C appears 
not to be a high priority for a group which face a plethora of more immediate health, welfare 
and social concerns (O’Brien et al., 2006). Among the most common reasons given by 
participants for not receiving treatment were that the service was not offered and that they 
were not appropriate for treatment. For entering treatment for Hepatitis C, guidelines 
recommend that a person has been abstinent from illicit substances and alcohol for six 
months (Swan et al., 2010) even though there is little evidence to indicate that treatment 
outcomes differ significantly between those who use drugs during treatment and those who 
do not (Hellard, Sacks-Davis, & Gold, 2009). Overall it would seem that the key to 
improving Hepatitis C management is in further educating at risk groups and developing an 
infrastructure which is non-judgemental, easy to access and provides continuity of care. 
Convenience seems to be an important factor in Hepatitis C management and IDUs 
themselves have suggested that a “one stop shop” where screening and treatment could be 
accessed would help minimise barriers (Swan et al., 2010).   
The prevalence of Hepatitis B reported is within the lower ranges of previously observed 
rates in prior research in an Irish context (Smyth et al., 1998; Cullen et al., 2000; Fitzgerald et 
al., 2001; O’Sullivan et al., 2004). It has been suggested that the lower rate of Hepatitis B 
detected among Irish IDUs may be attributable to the small number of cases with chronic 
infection and the availability of a rapid vaccine regimen for the virus, which can be 
completed in 3 weeks (Long, 2006). In line with the trend found with HIV and Hepatitis C, 
testing frequency is a worry, although a possible reason for not getting tested could be that 
persons had been vaccinated.   
There is little published data available regarding co-infection in Ireland (Long, 2006). In the 
present study, the prevalence of Hepatitis C/Hepatitis B co-infection was approximately 3% 
for those who had been tested for both viruses.  In line with findings from the wider 
literature, the incidence of HIV and Hepatitis C co-infection was more prevalent than 
Hepatitis B/Hepatitis C co-infection within the current sample. The prevalence of HIV and 
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Hepatitis C co-infection among IDUs at a European level is particularly high and continues to 
rise (WHO, 2006). In the present study, almost 73% of those who were HIV positive were 
also Hepatitis C positive. Given the increasing prevalence of this form of co-infection and the 
associated treatment complications, the prospect of increased health consequences would 
appear likely.  
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6. Recommendations 
Research represents a primary pillar of the National Drugs Strategy (Interim) 2009-2016, in 
which, the strategic aim of ensuring the availability of accurate, timely, relevant and 
comparable data on the extent and nature of problem substance use in Ireland, is emphasised. 
Contemporary research within the context of low threshold services and needle exchange 
programmes in Ireland is particularly sparse. Consequently, there is paucity of germane data 
available for evidence informed decision-making and policy formulation in this domain. The 
present study offers a contribution towards fulfilling national policy research objectives, and 
provides a foundation for the construction of an up to date evidence base in relation to Irish 
harm reduction services. Based on the research process and findings presented herein, a 
number of recommendations are proposed:   
6.1. Policy Based Recommendations 
 Sharing of injecting equipment and paraphernalia persists. The National Drugs 
Strategy (NDS) document Building on Experience (2001-2008) advocates that in 
order to reduce “the reported level of injecting drug misuse and the rates of sharing 
injecting equipment” (pp. 110) there should be “continued efforts to enhance harm 
reduction measures such as needle exchange facilities” (pp. 110) and “access for all 
injecting drug misusers to sterile injecting equipment” (pp. 124). In this regard, there 
is a need to ensure that needle exchange programmes are providing injecting 
equipment consistent with guidelines recommended in the international research (e.g. 
Strike et al., 2006) so as to optimise harm reduction.  Where deficits are identified in 
the provision of injecting equipment, reasons for these gaps should be examined and 
communicated to Health Service Executive suppliers, in the effort to eliminate 
equipment related barriers in supporting safer injecting practices among injecting drug 
users. 
 
 A major finding of the present study is the prevalence of blood-borne viruses (BBVs), 
coupled with insufficient levels of testing and low rates in uptake of treatment for 
Hepatitis C and HIV. Furthermore, the results indicate that frequency of testing is a 
concern. The evidence in previous studies suggests that convenience is an important 
factor for injecting drug users in management of BBVs and low-threshold services are 
ideally placed to attract clients which have not been previously screened. The 
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recommendation that screening is offered and promoted within harm reduction 
services, as advised by the National Hepatitis C strategy 2011-2014, the European 
Centre for Monitoring Disease and Drug Addiction (2010) and the World Health 
Organisation (2010), is therefore supported.  
 
 The proportion of assisted injecting and injecting in public places reported in the 
present study represents a significant amount of injecting drug users who are at 
elevated risk of severe health consequences. An emerging strategy designed to combat 
such risks is the development of medically supervised injecting centres (MSIC). Such 
amenities are currently not available in Ireland and such a strategy is not endorsed 
through national policy. Reference to drug consumption rooms was made in the 
National Drugs Strategy (NDS) document Building on Experience 2001-2008 which 
stated ‘the Review Group does not consider that the introduction of such forms of 
treatment is warranted at this time. However, the situation should be kept under 
review and the results of research, both national and international, should be 
monitored’ (Section 4.13.3.). The National Drugs Strategy (Interim) 2009-2016 
makes little elaboration on the issue. It is therefore advised that in line with the 
recommendation from the Strategic Response Group’s ‘A Better City for All’ report 
(Connolly, 2012), further consideration of safer injecting facilities in an Irish context 
is warranted in future national policy deliberations.  
6.2. Research Based Recommendations 
 The present study provides additional evidence that the population of Irish opiate 
users is ageing. As the needs of older drug users tend to be more complex, future 
research should address if services are structured to cater for impacts which may 
accompany this shift in age profile.   
 
 The gender ratio found in the present study supports previous findings which indicate 
that females may be under-represented in drug services. Future research should aim to 
explore the potential barriers for female drug users and investigate appropriate 
gender-specific approaches.  
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 As indicated by the present study, the level of substance use among the homeless 
population continues to present concern. As stated in the National Drugs Strategy 
(Interim) 2009-2016, gaps in the provision of treatment services for homeless drug 
users persist. Further research in the vein of Corr and Lawless (2005) is necessary to 
update research regarding meeting the needs of homeless drug users.   
 
 The present study indicates a high prevalence of poly-drug use and highlights the 
current patterns of use. Future research should examine needs, impact, harm reduction 
interventions, and treatment and rehabilitation options in relation to poly-drug use.    
 
 There has been little published data in Ireland regarding steroid use, or steroid users’ 
engagement with services. The findings of the present study are consistent with 
international and Irish research which suggests that steroid users are becoming more 
prevalent in harm reduction services. As a marginalised group with divergent 
characteristics, there is the need to develop an evidence base which explores the 
profile of harm within this group, and to identify tailored approaches within the 
context of low threshold services.   
 
 Findings for sharing of injecting equipment and paraphernalia in the present study 
were incongruous with results from previous research. Future research should further 
investigate rates of sharing and consider the appropriateness of conducting related 
research in the context of needle exchange services.  
 
 Findings concerning BBVs in the present study were based on self-report. In order to 
ascertain a definitive prevalence, future research which incorporates serological 
testing is advisable.  
 
 A significant concern presented by the current study is management of Hepatitis C in 
injecting drug users. As noted in the National Hepatitis C strategy 2011-2014, 
evaluation of different models of care is needed to address the range of barriers faced 
by injecting drug users so as the enhance treatment access, delivery, and adherence.  
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6.3. Practice Based Recommendations 
 There are varied issues and barriers around service access and service use amongst 
female and migrant drug users. It is recommended that services make continued 
efforts to adopt a pro-active stance in regard to these groups.   Service providers 
should monitor the level of service use by under-represented groups (e.g. numbers, 
profile and needs of under-represented groups) to ensure that services are attracting 
members of these groups and meeting their needs. A gendered approach which 
recognises the needs unique to females is advocated. In the effort to address barriers 
faced by migrant drug users to accessing services, implementation of the 
recommendations from Corr (2004) are advised: translated materials could help 
breach the language barrier and increase knowledge and perceived accessibility of 
services; outreach could help interaction with underrepresented migrant groups; 
recruitment of staff from such backgrounds could help to attract and engage users 
from these communities; and more flexible and appropriate services could respond to 
unique needs more effectively. 
 
 It is vital that services are familiar with the profile of poly-drug use among their client 
base and are able to identify individual harm reduction needs. The provision of 
continuous up-skilling for staff is necessary to offer appropriate harm reduction 
advice and to address the risk behaviours associated with different patterns of drug 
use. The same applies in emerging areas such as steroid use.  
 
 Given the prevalence of BBVs found in the present study, as well as the concerns 
presented in relation to access to testing and uptake in treatment, it is recommended 
that in the case on-site BBV management options are not available; services should 
further develop collaborative relationships with appropriate external agencies. It is 
further advised that ongoing up-skilling with regard to BBV education, testing 
regimes, and treatment options, is provided for staff.  
  
 A high proportion of high risk behaviours such as injecting in to the groin/neck and 
not rotating injecting sites were found in the present study. Thus, the findings 
highlight the importance of the role of safer injecting workshops and suggest that 
there is a need to ensure that every effort is being made to direct clients to such a 
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service. Services should encourage client participation in safer injecting workshops 
irrespective of whether clients are newly injecting or have longer injecting careers. 
 
 Drug use does not exist in isolation. The complex of personal and structural problems 
faced by drug users, particularly those who are homeless, requires a multi-disciplinary 
approach to address their needs.  Services should continue to strive to provide a case 
management approach that is client-centred.  Such an approach requires greater 
collaboration and integration across the range of voluntary and government 
organisations involved in the provision of homeless, drug, and health services. Re-
skilling of staff in providing a multi-disciplinary spectrum of care also requires 
increased interagency transfer of training knowledge. 
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Appendix 
Substance Use in Detail 
Heroin use. As illustrated in Table 29, approximately 86% of participants (n=291) 
reported using heroin in the past month. In total, participants who used heroin were found to 
consume an average of 2.35 bags per day (SD=1.75) and spent an average of €45.72 per day 
(SD=32.21). Heroin use in the last week ranged from 0-7 days, with heroin being used on an 
average of 4.66 days per week (SD =2.62). In the previous four week period, heroin use 
ranged from 1-28 days, with heroin being consumed on an average of approximately 19 out 
of 28 days (M=18.50, SD=10.22).  
Table 29: Descriptive statistics for heroin use 
 Total Heroin/no 
methadone 
Heroin/prescribed 
methadone 
Heroin/illicit 
methadone 
Participants 290 134 148 8 
Percentage 86.09 39.64 43.79 2.36 
Mean Age (SD) 34.18 (7.41) 33.59 (7.59) 34.89 (7.21) 31.13 (6.19) 
Range (use per day) 0.5-10 bags 0.5-10 bags 0.5-10 bags 1-4 bags 
Mean (use per day) 2.35 bags 2.76 bags 1.98 bags 1.95 bags 
Std. Deviation (use per day) 1.75 bags 1.96 bags 1.4 bags 1.33 bags 
Range (price per day) 10-200 € 10-200 € 10-125 € 20-50 € 
Mean (price per day) 45.72 € 54.32 € 38.35 € 33.15 € 
Std. Deviation (price per day) 32.21 € 37.90 € 24.20 € 16.38 € 
Range (frequency last week) 0-7 days 0-7 days 0-7 days 2-7 days 
Mean (frequency last week) 4.66 days 5.55 days 3.85 days 6 days 
Std. Deviation (frequency last 
week) 
2.62 days 2.33 days 2.67 days 1.66 days 
Range (frequency last month) 1-28 days 1-28 days 1-28 days 2-28 days 
Mean (frequency last month) 18.50 days 21.98 days 15.11 days 21.75 days 
Std. Deviation (frequency last 
month) 
10.22 days 8.92 days 10.33 days 8.09 days 
 
Table 30 overleaf describes that the primary route of heroin administration was injection 
(n=245). Participants also reported using a combination of smoking/injecting (n=34) and 
smoking (n=6).  
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Table 30: Route of heroin administration 
 Total 
 n % 
Injecting 245 84.48 
Smoking 6 2.07 
Injecting/Smoking 34 11.73 
Unknown 5 1.72 
Total 290 100 
 
 Methadone use. As illustrated in Table 31, over 51% of participants (n=175) reported 
using methadone in the past month. In total, participants who used methadone were found to 
consume an average of 71.04millilitres per day (SD=27.20). Methadone use in the last week 
ranged from 0-7 days, with the substance being used on an average of 6.78 days per week 
(SD=1.11). In the previous four week period, methadone use ranged from 2-28days, with 
methadone being consumed on an average of approximately 27 out of 28 days (M=26.95, 
SD=4.61). 
Just under 50% of participants (n=167) reported using prescribed methadone in the past 
month. Participants who used prescribed methadone were found to consume an average of 
72.72millilitres per day (SD=26.75). Prescribed methadone use in the last week ranged from 
0-7 days, with the substance being used on an average of 6.90 days per week (SD=0.74). In 
the previous four week period, prescribed methadone use ranged from 2-28days, with 
methadone being consumed on an average of approximately 27 out of 28 days (M=27.46, 
SD=3.36). 
Approximately 2% of participants (n=8) reported using methadone which had been bought on 
the street in the last month. Participants who used illicit methadone were found to consume 
an average of 46.25millilitres per day (SD=24.46) and spent an average of €13.38 per day. 
Illicit methadone use in the last week ranged from 0-7 days, with the substance being used on 
an average of 4 days per week (SD=2.69). In the previous four week period, illicit methadone 
use ranged from 2-28days, with methadone being consumed on an average of approximately 
16 out of 28 days (M=16.25, SD=10.41). 
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Table 31: Descriptive statistics for methadone use 
 Total Prescribed 
Methadone 
Illicit Methadone 
Participants (n) 175 167 8 
Percentage 51.78% 49.41% 2.37% 
Mean Age (SD) 34.59 (7.14) 34.75 (7.14) 31.13 (6.19) 
Range (use per day) 1-160 ml 1-160 ml 20-100 ml 
Mean (use per day) 71.04 72.27 ml 46.25 ml 
Std. Deviation (use per day) 27.20 26.75 ml 24.46 ml 
Range (price per day) N/A N/A 2-20 € 
Mean (price per day) N/A N/A 13.38 € 
Std. Deviation (price per day) N/A N/A 7.05 € 
Range (frequency last week) 0-7 days 0-7 days 0-7 days 
Mean (frequency last week) 6.76 days 6.90 days 4 days 
Std. Deviation (frequency last week) 1.11 days 0.74 days 2.69 days 
Range (frequency last month) 2-28days 2-28 days 2-28 days 
Mean (frequency last month) 26.95 days 27.46 days 16.25 days 
Std. Deviation (frequency last month) 4.61 days 3.36 days 10.41 days 
 
 Cannabis use. As illustrated in Table 32, approximately 24% of participants (n=82) 
reported using cannabis in the past month. In total, participants who used cannabis were 
found to consume an average of 4.83 spliffs per day (SD=4.30). Cannabis use in the last week 
ranged from 0-7 days, with the substance being used on an average of 4.89 days per week 
(SD=2.35). In the previous four week period, cannabis use ranged from 1-28days, with 
cannabis being used on an average of approximately 19 out of 28 days (M=19.41, SD=9.44). 
The majority of participants could not give an estimation of the price of the cannabis used per 
day. All clients who used cannabis reported smoking as the route of administration. 
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Table 32: Descriptive statistics for cannabis use 
 Total 
Participants (n) 82 
Percentage 24.26% 
Mean Age (SD) 34.05 (7.71) 
Range (use per day) 1-20 spliffs 
Mean (use per day) 4.83 spliffs 
Std. Deviation (use per day) 4.30 spliffs 
Range (price per day) Unknown 
Mean (price per day) Unknown 
Std. Deviation (price per day) Unknown 
Range (frequency last week) 0-7 days 
Mean (frequency last week) 4.89 days 
Std. Deviation (frequency last week) 2.35 days 
Range (frequency last month) 1-28 days 
Mean (frequency last month) 19.41 days 
Std. Deviation (frequency last month) 9.44 days 
 
 Alcohol use. As illustrated in Table 33 overleaf, approximately 22% of participants 
(n=74) reported using alcohol in the past month. Participants who used alcohol were found to 
consume an average of 13.97 units per day (SD=9.70) and spent an average of €16.56 per day 
(SD=14.75). Alcohol use ranged from 0-7 days in the last week, with alcohol being 
consumed on an average of 3.63 days per week (SD=2.54). In the previous four week period, 
alcohol use ranged from 1-28days, with alcohol being consumed on an average of 
approximately 14 out of 28 days (M=13.95, SD=10.08). 
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Table 33: Descriptive statistics for alcohol use 
 Total 
Participants (n) 74 
Percentage 21.89% 
Mean Age (SD) 35.29 (8.99) 
Range (use) 1.44-48 units 
Mean (use) 13.97 units 
Std. Deviation (use) 9.70 
Range (price) 1-100 € 
Mean (price) 16.56 € 
Std. Deviation (price) 14.75 € 
Range (frequency last week) 0-7 days 
Mean (frequency last week) 3.63 days 
Std. Deviation (frequency last week) 2.54 days 
Range (frequency last month) 1-28 days 
Mean (frequency last month) 13.95 days 
Std. Deviation (frequency last month) 10.08 ays 
 
Benzodiazepine use. As illustrated in Table 34, approximately 32% of participants 
(n=109) reported using benzodiazepines in the past month. In total, participants who used 
benzodiazepines were found to consume an average of 72.76milligrams per day (SD=99.40). 
Benzodiazepine use in the last week ranged from 0-7 days, with the substance being used on 
an average of 5.69 days per week (SD=3.23). In the previous four week period, 
benzodiazepine use ranged from 1-28days, with benzodiazepines being consumed on an 
average of approximately 22 out of 28 days (M=22.07, SD=9.24). 
Just under 15% of participants (n=49) reported using prescribed benzodiazepines in the past 
month. Average consumption for participants who had obtained benzodiazepines through 
prescription amounted to 23.40 milligrams per day (SD=18.50). Prescribed benzodiazepines 
use in the last week ranged from 0-7 days, with the substance being used on an average of 
6.71 days per week (SD=1.09). In the previous four week period, prescribed benzodiazepines 
use ranged from 8-28days, with benzodiazepines being consumed on an average of 
approximately 27 out of 28 days (M=26.56, SD=4.368).The types of benzodiazepines used 
by this group included Zimovane, Diazepam, D5, D10, Dalmane, and Valium.  
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Approximately 17% of participants (n=56) reported using benzodiazepines which had been 
bought on the street in the last month. Participants who used illicit benzodiazepines were 
found to consume an average of 101.73 milligrams per day (SD=113.54) and spent an 
average of €19.08 per day. Illicit benzodiazepine use in the last week ranged from 0-7 days, 
with the substance being used on an average of 4.38 days per week (SD=2.67). In the 
previous four week period, illicit benzodiazepine use ranged from 1-28days, with 
benzodiazepines being consumed on an average of approximately 18 out of 28 days 
(M=18.07, SD=10.37).The main types of illicit benzodiazepines used included D5, D10, 
Diazepam, Zimovane, Valium, and Dalmane 
Approximately 1% of participants (n=4) reported using a combination of prescribed and 
illicit benzodiazepines in the last month. Participants who used illicit benzodiazepines were 
found to consume an average of 212.25 milligrams per day (SD=121.64) and spent an 
average of €28.50 per day. In this group, benzodiazepines were used every day in the past 
week and every day in the past 4 weeks. The types of benzodiazepines used by this group 
included D2, D5, D10, D20, D30, Diazepam and Xanax.  
Table 34: Descriptive statistics for benzodiazepine use 
 Total Prescribed 
Benzodiazepines 
only 
Illicit 
Benzodiazepines 
only 
Prescribed & 
Illicit 
Benzodiazepines 
Participants (n) 109 49 56 4 
Percentage 32.25% 14.50% 16.57% 1.18% 
Mean Age (SD) 33.89 (6.72) 34.51 (6.65) 33.51 (6.90) 31.5 (3.20) 
Range (use per day) 2-450 mg 2-100 mg 5-450 mg 40-350 mg 
Mean (use per day) 72.76 mg 23.40 mg 101.73 mg 212.25 mg 
Std. Deviation (use per day) 99.40 mg 18.50 mg 113.54 mg 121.64 mg 
Range (price per day) N/A N/A 0-60 € 7-45 € 
Mean (price per day) N/A N/A 19.08 € 28.50 € 
Std. Deviation (price per day) N/A N/A 18.35 € 13.68 € 
Range (frequency last week) 0-7 2-7 days 0-7 days 7days  
Mean (frequency last week) 5.69 days 6.71 days 4.38 days 7 days 
Std. Deviation (frequency last 
week) 
3.23 days 1.09 days 2.67 days 0 days 
Range (frequency last month) 1-28days 8-28 days 1-28 days 28 days 
Mean (frequency last month) 22.07 days 26.56 days 18.07 days 28 days 
Std. Dev (frequency last month) 9.24 days 4.68 days 10.37 days 0 days 
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Steroid use. Approximately 7% of participants (n=25) reported using steroids in the 
past month. Mean age of steroid users was 28.84 years (SD= 7.14). All participants reported 
injecting as the route of administration. Participants who used steroids reported using a range 
of substances including anabolic steroids, Nandrolone, Deca Durbolin, Sustanon, Equipoise, 
Tri-trenabol, Testorone Propionate, Human Growth Hormones, Trebolone, Masteron 
propionate, GHRP6, HCG, and Melatonin injections. The majority of steroid users used at 
least two of these substances in combination. 
Cocaine use. As illustrated in Table 35, just over 6% of participants (n=21) reported 
using cocaine in the past month. In total, participants who used cocaine were found to spend 
an average of €79.26 per day (SD=49.38). A reliable statistic for use of cocaine in terms of 
amounts could not be extrapolated as these data were reported differentially. Cocaine use in 
the last week ranged from 0-7 days, with the substance being used on an average of 2.22 days 
per week (SD=2.32). In the previous four week period, cocaine use ranged from 1-28days, 
with cocaine being used on an average of approximately 8 out of 28 days (M=8.15, 
SD=9.16). In terms of route of administration, 10 participants reported injecting, 4 
participants reported snorting, and 1 participant reported smoking. Six participants did not 
report route of administration.   
Table 35: Descriptive statistics for cocaine use 
 Total 
Participants (n) 21 
Percentage 6.21% 
Mean Age (SD) 34 (8.16) 
Range (use per day) Unknown 
Mean (use per day) Unknown 
Std. Deviation (use per day) Unknown 
Range (price per day) 0-200 € 
Mean (price per day) 79.26 € 
Std. Deviation (price per day) 49.38 € 
Range (frequency last week) 0-7 days 
Mean (frequency last week) 2.2 days 
Std. Deviation (frequency last week) 2.32 days 
Range (frequency last month) 1-28 days 
Mean (frequency last month) 8.15 days 
Std. Deviation (frequency last month) 9.16 days 
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Mephedrone use. As illustrated in Table 36, just over 6% of participants (n=21) 
reported using mephedrone in the past month. In total, participants who used mephedrone 
were found to consume an average of 1.45 bags per day (SD=0.85). Mephedrone use in the 
last week ranged from 0-7 days, with the substance being used on an average of 2.29 days per 
week (SD=2.16)and spent an average of €36.42 per day (SD=25.09). In the previous four 
week period, mephedrone use ranged from 1-28days, with mephedrone being used on an 
average of approximately 8 out of 28 days (M=7.86, SD=7.97). Approximately 95% of 
participants (n=20) who used mephedrone reported injecting as the route of administration 
and 5% of participants (n=1) who used mephedrone reported smoking as the route of 
administration. 
Table 36: Descriptive statistics for mephedrone use 
 Total 
Participants (n) 21 
Percentage 6.21% 
Mean Age (SD) 36.48 (8.58) 
Range (use per day) 0.5-5 bags 
Mean (use per day) 1.45 bags 
Std. Deviation (use per day) 0.85 bags 
Range (price per day) 0-80 € 
Mean (price per day) 36.42 € 
Std. Deviation (price per day) 25.09 € 
Range (frequency last week) 0-7 days 
Mean (frequency last week) 2.29 days 
Std. Deviation (frequency last week) 2.16 days 
Range (frequency last month) 1-28 days 
Mean (frequency last month) 7.86 days 
Std. Deviation (frequency last month) 7.97 days 
 
Crack use. As illustrated in Table 37, just under 6% of participants (n=20) reported 
using crack in the past month. In total, participants who used crack were found to spend an 
average of €68.15 per day (SD=38.94). A reliable statistic for use of crack in terms of 
amounts could not be extrapolated as these data were reported differentially. Crack use in the 
last week ranged from 0-7 days, with the substance being used on an average of 2.75 days per 
week (SD=2.68). In the previous four week period, crack use ranged from 1-28days, with 
cocaine being used on an average of approximately 11 out of 28 days (M=11.4, SD=9.98). 
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Eighteen participants reported smoking as the route of administration and one participant 
reported injecting as the route of administration. One participant did not report their route of 
administration for crack.  
Table 37: Descriptive statistics for crack use 
 Total 
Participants (n) 20 
Percentage 5.92% 
Mean Age (SD) 34.1 (6.3) 
Range (use per day) Unknown 
Mean (use per day) Unknown 
Std. Deviation (use per day) Unknown 
Range (price per day) 25-150 € 
Mean (price per day) 68.15 € 
Std. Deviation (price per day) 38.94 € 
Range (frequency last week) 0-7 days 
Mean (frequency last week) 2.75 days 
Std. Deviation (frequency last week) 2.68 days 
Range (frequency last month) 1-28 days 
 
Amphetamines use. Approximately 1% of participants (n=4) reported using 
amphetamines in the past month. Mean age of amphetamine users was 35.5 years (SD=9.76).  
Other substance use. Approximately 4% of participants (n=14) reported using 
substances in the past month which were not listed on the questionnaire. Five participants 
reported using anti-depressants. Types of anti-depressants used included Zispin (n=4), 
Clonactil (n=1) and Mirap (n=1). Four participants had obtained anti-depressants on 
prescription and were found to consume an average of 30 milligrams per day (SD=12.24). All 
participants used prescription anti-depressants 7 days in the last week and 28 days in the last 
4 weeks. One participant had obtained anti-depressants illicitly, paying €2 for 30 milligrams 
of Zispin and using the substance once in the past 4 weeks. Other types of substances used 
included Olanzapine (n=1), Ketamine (n=1), lidocaine (n=1), rohypnol (n=1) and MDPV 
(n=1). 1 participant had obtained and was using a substance which they had acquired through 
the internet but did not know what type of substance it was.  
 
Merchants Quay Ireland  
PO Box 11958, Dublin 8
Location: Merchants Quay Ireland, 
28 Winetavern Street, Dublin 8
Direct Line: 01 524 0160 
Email: info@mqi.ie
Fax: 01 524 0946
www.mqi.ie
© 2013 Merchants Quay Ireland

